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SUMMARY
This thesis presents a case -  control disease association research project examining 
association between single nucleotide polymorphisms (SNPs) of the P53R2 and 
Reprimo genes and colorectal cancer (CRC).
Identifying the genetic risk factors may help to reduce the incidence of CRC by 
allowing identification of individuals at increased CRC risk through genetic 
screening. Individuals identified as having increased CRC risk could then have 
tailored management aiming to reduce their risk and detect CRC at an early, 
potentially curable stage.
P53R2 and Reprimo are both involved in cell cycle control and DNA repair. P53R2 
supplies deoxyribonucleotides for repair of damaged DNA and Reprimo is involved in 
cell cycle arrest in response to genotoxic stress, allowing DNA repair to take place or 
for apoptosis. Both genes are induced by the tumour suppressor gene TP53. 
Dysfunction of P53R2 or Reprimo may lead to errors in DNA repair or cell cycle 
arrest, mechanisms that are recognised in carcinogenesis. SNPs are known to be able 
to alter gene function and it is thought that SNPs may account for some of the 
molecular pathology involved in common complex diseases such as cancer.
Two SNPs were studied, P53R2 C>G 4696 and Reprimo G>C 842, using a case 
control method. Cases with histologically proven CRC were compared with two 
control populations; young, healthy individuals and individuals with diverticular 
disease (DD).
DNA was obtained from buccal cell biopsies and the populations genotyped using an 
allele specific polymerase chain reaction (PCR) or polymerase chain 
reaction/restriction fragment length polymorphism (PCR/RFLP) methods. Tests for 
Hardy-Weinberg equilibrium (HWE) and allelic- and genotype-disease association 
were performed using an on line SNP-disease association calculator.
An association between the Reprimo G>C 842 C allele and CRC was detected on 
heterozygous and allele positivity testing when using the young, healthy population as 
a control. However, this association is likely to be a false positive result confounding 
factors and was not replicated when using the matched DD population. The DD 
population was found to deviate from HWE with respect to Reprimo G>C 824 and 
therefore a disease association may exist. Otherwise no associations between the 
study SNPs and CRC were detected.
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PREFACE
i. Problem statement
Colorectal cancer (CRC) is a fatal disease that represents a significant health 
problem in terms of numbers of people affected and burden on health care 
resources. Although advances in surgical technique and medical science have 
resulted in improved diagnostic technology, increasingly complex surgery and 
improved anaesthetic and intensive care resulting in lower operative mortality, 
overall mortality due to CRC over the past 40 years has not been significantly 
reduced (Little and Faivre, 1999, 1998, Grogan et ah, 1996, Cunningham and 
Dunlop, 1996). The probable reason for the unchanging mortality is that the 
diagnosis of CRC is made at an often advanced and incurable stage, and that this 
situation has not changed with advances in surgical and medical science. It is likely 
that mortality from CRC will remain high until it becomes possible to diagnose the 
disease at an earlier, curable stage. This would, in part, involve being able to 
identify and treat individuals with a greater risk of developing colorectal cancer at a 
pre-symptomatic stage.
Screening of targeted individuals is, at present, limited to those with symptoms 
suggestive of CRC or those with strong family histories and usually involves faecal 
occult blood detection, endoscopic or x-ray examination to identify suspicious 
colonic lesions. Genetic screening is limited to those individuals with family 
histories suggestive of the recognized familial syndromes leading to the 
development of colorectal cancer.
The molecular biology of CRC has started to be unravelled and the various genetic 
steps necessary for cancer development have started to be understood. Analysis of 
the genotype of tumours can yield more accurate prognostic information than
traditional stage and grade information and can guide treatment strategies, 
particularly adjuvant chemoradiotherapy.
Hereditary forms of CRC, although rare, have long been recognized and recently 
the molecular biology of some of these syndromes has been determined, allowing 
genetic screening and guided therapy. As knowledge of CRC genetics advances, 
more genes are implicated in its development and the possibility of genetic 
screening to identify individuals at greater risk of developing the disease becomes 
more feasible.
Paralleling advances in cancer genetics have been advances in genetic technology 
allowing easier and cheaper methods of gene identification and functional analysis, 
allowing more efficient investigation of candidate disease genes and genetic 
screening.
Reprimo and p53R2 are both genes involved in DNA repair and failure of DNA 
repair mechanisms are fundamental in carcinogenesis. Variations in genes such as 
single nucleotide polymorphisms may lead to functional variations. Although SNPs 
of Reprimo and p53R2 have been discovered it is not known whether these 
variations have any effect on their functions and so potential to modulate DNA 
repair. If so it is conceivable that SNPs of Reprimo and p53R2 could have variable 
DNA repair effectiveness that could lead to DNA replication errors, a fundamental 
step in carcinogenesis. As such Reprimo and p53R2 present themselves as candidate 
genes for investigation into association with cancer.
Jii. Aim
With these ideas in mind the aim of this research is to investigate possible 
association between the Reprimo G>C 824 and p53R2 C>G 4696 SNPs and CRC 
using a case-control study method.
iii. Research approach
To achieve this aim Chapter 1 provides the background to the research. The current 
understanding of the molecular biology of CRC is reviewed. Single Nucleotide 
Polymorphisms are defined, their effects on gene function explained and their role 
in carcinogenesis reviewed. The two study genes Reprimo and p53R2 are 
introduced and a detailed description of their genetics is given. Details of the 
discovery of their SNPs are also given. The control disease diverticulosis is 
reviewed in terms of its epidemiology, pathology and genetics.
The Materials and Methods are described in Chapter 2 where details of the 
laboratory techniques used to genotype the study populations and the statistical 
methods used to test the study genes for association with CRC are given.
The preliminary work involved in designing and developing the research methods 
and the problems encountered in designing the methods are given in Chapter 3. 
Chapter 4 presents the results of the research. Population demographics and 
comparisons, DNA collection and isolation results and results of genotyping are 
given. Examples of typical electrophoresis gels that display genotypes are shown 
and the results of the statistical analyses of the genotyping data are presented. 
Chapter 5 discusses the research in the context of the current understanding of the 
topic. The research method is discussed in terms of its strengths and weaknesses. 
Further work stimulated by this study is also discussed.
CHAPTER 1
BACKGROUND 
1.1 COLORECTAL CANCER
1.1.1 Definition
CRCs are malignant tumours of the large bowel. The majority arise from the 
glandular mucosa and are termed adenocarcinomas, and this thesis is concerned 
only with adenocarcinomas.
1.1.2 Epidemiology.
CRC is the second most common cause of death from malignant disease accounting 
for nearly 400,000 deaths per year worldwide (2001). In England and Wales CRC 
accounts for 13% of all cancers. Only lung cancer and prostate cancer in men and 
lung cancer in women are more frequent and lung cancer more lethal in both sexes.
1.1.3 Incidence and Mortality.
The incidence of CRC between 2002 -  2004 was 34,395 cases in the United 
Kingdom and 1,957 in Wales. The mortality from CRC between 2002-2004 was 
15,908 in the United kingdom and 905 in Wales (Statistics, 2007)
The survival from CRC is moderate, with a five-year survival rate of around 40%. 
Colorectal cancer occurs more frequently in men with an aged-standardised ratio of 
1.5:1. Incidence rises steadily with age, and the disease is most common in the 
seventh decade of life.
1.1.4 Geography
CRC is more common in developed countries. Thus incidence rates are higher in 
Europe, North America and Australia, but lower in the developing regions of Asia 
and Africa. However migrants to areas of higher incidence acquire the local risk, 
suggesting a significant environmental risk factor in the aetiology of CRC.
Despite similar incidence rates survival from CRC is higher in Australia and North 
America than in Europe. England and Wales has poorer survival rates than Europe. 
This variation in survival may reflect earlier detection of CRC and better 
management in those countries with improved survival.
Within England and Wales the incidence of CRC is highest in Wales and lowest in 
North Thames. Mortality is also highest in Wales and lowest in North Thames. This 
may well reflect variations in health service provision.
1.1.5 Diagnosis.
The majority of cases of CRC are diagnosed following individuals presenting with 
the symptoms of the disease (as discussed below). Unfortunately symptomatic CRC 
usually represents relatively advanced disease, and so less likelihood of cure. A 
proportion of CRC is diagnosed by screening high risk individuals on the basis of 
family history. Some CRC is diagnosed incidentally during investigation of other 
problems.
Diagnosis depends on biopsying suspicious lesions found on physical examination, 
endoscopy and/or radiological investigations. Guidelines have been developed to 
direct physicians in the management of CRC and particularly in referral of patients 
with high risk symptoms or family history (2004, Ireland, 2001). The aim of such
guidelines is to minimise diagnostic delay from the onset of symptoms and ensure 
patients receive optimal treatment based on the best available evidence.
1.1.6 Pathology.
Colorectal adenocarcinomas arise from the glandular epithelium of the colon and 
rectum. At variable times in their development they metastasise to the local lymph 
nodes via lymphatic channels and to distant organs, commonly the liver, via the 
blood stream (haematogenous spread). The majority of colorectal cancers develop 
in pre-existing adenomatous polyps and there is a well defined progression from 
normal mucosa to adenomatous polyps to malignant carcinoma. This progression is 
mirrored by increasing dysplasia within the tissue.
As the tumours grow with in the lumen of the bowel they may be manifest 
symptomatically by blood loss per rectum due to tumour bleeding, by an alteration 
in the bowel habit due to obstruction of the passage of stools through the bowel or 
due to excessive mucus production. The tumours may grow through the bowel wall 
and invade adjacent tissues and organs. Tumours that have spread to the liver can 
cause jaundice and liver failure, and this is a frequent cause of death in CRC. 
Bleeding tumours may present with anaemia from slow bleeding or catastrophic 
haemorrhage when significant blood vessels are invaded. Obstructing tumours may 
present with chronic obstruction or acute obstruction with bowel perforation. 
Although CRC may present with a variety of different symptoms and clinical signs 
the common denominator is that for the tumours to be clinically manifested they are 
usually at an advanced stage of development when metastatic spread is more likely 
and cure, which depends on complete tumour excision, is less likely.
1.1.7 Tumour Stage.
Tumour stage refers to the stage of development or growth of cancers and is used to 
make prognostic assumptions and therefore plan treatment. Indeed survival 
following diagnosis of cancer is related to tumour stage and when cancers are 
diagnosed it is important to determine their stage. Although most cancers evolved 
their own specific staging systems (for example Duke’s stage for rectal cancer) 
there has been consensus on standardising staging using the TNM system, 
developed by the UICC (Union Intemacional Contra la Cancrum). TNM stands for 
Tumour, (lymph) Nodes, Metastases and cancers are staged according to the size of 
the primary tumour, presence of lymph nodes and presence of distant metastases. 
Having established the TNM stage for a cancer a stage group can be assigned. Once 
a cancer has been staged assumptions regarding curability can be made according to 
prior determined stage related prognosis and decisions made regarding the most 
suitable treatment strategies. Clearly in order to allow this, staging needs to be a 
pre-treatment/operative process utilising various diagnostic modalities principally 
computed tomography (CT) and ultra sound scanning (USS), although as 
technology advances more sophisticated scans are becoming available, such as 
magnetic resonance imaging, endorectal ultrasound and positron emission 
tomography. Definitive staging for resected tumours is dependent on pathological 
examination of the resection specimens and this information is used to plan post­
operative adjuvant chemo- or radiotherapy.
The Tables below show how CRC is staged (Tables 1.1-1.3) and how stage relates 
to survival (Table 1.4).
DUKE’S STAGE
A Tumour confined to bowel wall, no positive lymph nodes.
B Tumour growth beyond muscularis propria, no positive lymph nodes.
C l Tumour growth beyond muscularis propria, positive lymph nodes but apical
node negative.
C2 Tumour growth beyond muscularis propria, positive apical lymph node.
Table 1.1: Dukes’ stage for rectal cancer (the apical lymph node is the node closest to the point 
at which the blood vessels are ligated in a resected tumour specimen).
Stage T N M
X Incomplete information
is Tumour “in-situ”, confined to 
mucosa.
0 No tumour found No lymph nodes 
involved
No metastases
1 Tumour involves submucosa. 1-3 local lymph 
nodes involved
Evidence of 
metastases
2 Tumour involves muscularis 
propria.
> 4 local lymph 
nodes involved
3 Tumour breeches muscularis 
propria.
4 Tumour involves adjacent 
organs/tissues or has perforated.
Table 1.2: TNM stages for colorectal cancer (N stage is only ever 0,1 or 2 and M stage only
ever 0 or 1).
STAGE GROUP T N M DUKE’S
0 Carcinoma In-situ 0 0
I 1 - 2 0 0 A
IIA 3 0 0 B
I1B 4 0 0 B
IIIA 1-2 1 0 C
IIIB 3-4 1 0 C
me Any 2 0 C
IV Any any 1
Table 1.3: Stage grouping for colorectal cancer.
STAGE GROUP PERCENTAGE 5 YEAR SURVIVAL
I 93
IIA 85
IIB 72
IIIA 83
IIIB 64
me 44
IV 8
Table 1.4: Five year survival according to stage for colorectal cancer (O’Connell et al., 2004).
As Table 4 shows lower tumour stage is associated with better survival, and so it is 
desirable to diagnose CRC at an early stage if  possible. However, as mentioned 
previously, CRC tends not to produce symptoms at the early stages, so is not 
clinically manifest and therefore diagnosed so frequently at the early, better 
prognostic stages. Indeed almost a third of CRC presents with metastatic spread 
with very little likelihood of cure (Table 1.5). Therefore in order to improve
survival from CRC it is necessary to develop methods to detect the disease at a pre- 
symptomatic, more favourable stage.
DUKE’S STAGE FREQUENCY AT DIAGNOSIS
A 11%
B 35%
C 26%
METASTATIC DISEASE 29%
Table 1.5: Stage frequency at diagnosis of CRC.
1.1.8 Tumour grade.
Tumour grade refers to how the histological appearance of the tumour cells relates 
to tumour behaviour. Despite all adenocarcinomas being malignant, that is they 
have the potential to metastasize, there is a spectrum of ‘aggressiveness’ from low- 
grade tumours that histologically more closely resemble the tissue from which they 
derive (well differentiated) and tend to grow more slowly and metastasize later, 
and, to high grade tumours that grow rapidly, invade local tissues and metastasize 
early, and histologically are more distinct from the original tissue (poorly 
differentiated). Knowledge of a tumour’s grade adds to prognostic information with 
higher grade, more poorly differentiated tumours tending to have a worse prognosis. 
Tumour grade influences treatment strategies, particularly adjuvant therapies.
1.1.9 Aetiology of CRC (Figure 1.1).
80% of CRC cases arise spontaneously with no known pre-existing inherited 
predisposition (and it is with this group that this thesis is concerned). Five percent
of cases are inherited due to autosomal dominantly inherited genetic conditions 
including familial adenomatous polyposis (FAP) and related conditions (M Y H - 
associated polyposis and the hamartomatous syndromes), and hereditary non­
polyposis colon cancer (HNPCC). Around 15% cases are familial and are identified 
by clustering of the disease within families and early diagnosis.
Aetiology of CRC
□ HNPCC
■ FAP and related polyposes
□ FAMIUALCKC
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Figure 1.1 Aetiology o f CRC
1.1.10 Environmental Aetiological Factors.
1.1.10.1 Diet.
Diet has been considered one of the most important environmental aetiological 
factors for the development of CRC for a long time. Increased risk of CRC has been 
shown to be associated with increased faecal pH, increased concentration of faecal 
bile acids and decreased faecal bulk (Thorton, 1981, Jenson et ah, 1982, Reddy and 
Wynder, 1977). As dietary fibre increases faecal bulk and lowers faecal pH it was 
thought that it may protect against CRC (Eastwood, 1987). Furthermore the 
dilutional effect of increased faecal bulk from fibre was postulated to reduce the
exposure to carcinogens and it was speculated that specific anti-carcinogenic agents 
may be present in fruit and vegetables (Lampe et al., 1992). Red meat and 
processed meats were also implicated as an environmental risk factor for CRC 
(Willett et al., 1990, Goldbohm et al., 1994). Proposed mechanisms for the 
increased CRC risk from red meat included: increased bile acid secretion; mitogenic 
effects of diacylglyceride products of fat digestion; effects of increased saturated 
fatty acids or decreased polyunsaturated fatty acids on insulin receptors; 
carcinogenic effects of increased colonic ammonia from breakdown of dietary 
protein; effects of increased iron; enhanced production of carcinogenic N-nitroso 
compounds; formation of carcinogenic heterocyclic amines and polycyclic aromatic 
hydrocarbons by high temperature cooking and naked flames (Norat et al., 2002). 
Therefore the role of diet in CRC has been extensively studied (Glade, 1999, 
Michels et al., 2000). However the only consistent association that has been 
demonstrated from case control studies is that of an inverse association between 
vegetable intake and CRC.
Dietary fibre has not been shown to have a clear association with CRC (1997, 
Byers, 2000, Kim, 2000) and indeed no protective effects of wheat bran have been 
demonstrated in randomised controlled trials (Byers, 2000).
No statistically significant association has been demonstrated between meat 
consumption and CRC in meta-analyses (Sandhu et al., 2001).
1.1.10.2 Obesity.
Obesity has been shown to be a risk factor for developing CRC. A BMI of greater
9 9than 25kg/m or 30kg/m have been shown to increase an individuals risk by 15% 
and 33% respectively (Bergstrom et al., 2001).
1.1.10.3 Exercise.
The risk of Colon cancer but not rectal cancer has been shown to be reduced by 
physical exercise. A 50% risk reduction can be achieved with high levels of 
exercise, with the effect being strongest for men (Colditz et al., 1997).
1.1.10.4 Smoking.
Long term tobacco smokers are at increased risk of developing CRC with relative 
risks of 1.5 -  3. 20% of CRC cases in the USA are probably as a result of smoking 
(Giovannucci, 2001).
1.1.10.5 Alcohol.
There is no clear evidence for the relationship between 
CRC. Meta-analysis of the available studies shows 
(Corrao et al., 1999).
1.1.10.6 Hormone Therapy.
Postmenopausal oestrogen replacement therapy has been shown to reduce the risk 
of colon cancer (Crandall, 1999). Colocyte oestrogen receptor methylation has been 
proposed as an early event in colorectal carcinogenesis and demethylation from 
exogenous oestrogen may account for the reduced risk (Issa et al., 1994). However 
the reduction in cancer risk is offset by an increased risk of cardiovascular events, 
pulmonary embolism and invasive breast cancer (Rossouw et al., 2002). The 
protective effects of HRT do not endure after stopping the treatment and there does
alcohol consumption and 
significant heterogeneity
not seem to be any effect on rectal cancer risk (Goldstein et al., 1999, Nanda et al., 
1999).
There may be some risk reduction from oral contraceptives (Franceschi and 
Vecchia, 1998).
1.1.11 Colorectal Cancer Genetics.
Of all the cancers the genetics of CRC is perhaps the best understood and most 
extensively studied. This is due to it being a common disease and having a clearly 
understood pre-malignant phenotype; the adenomatous polyp. Extensive studies of 
the genetic changes that occur during the progression from normal mucosa to 
carcinoma have led to the development of a genetic paradigm; the “adenoma- 
carcinoma sequence”(Vogelstein et al., 1988, Fearon and Volgestein, 1990). This 
paradigm shows how the step-wise accumulation of genetic mutations in key 
regulatory genes leads to increasing cellular instability, uncontrolled growth and 
metastatic spread (Figure 1.2).
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Figure 1.2: The adenoma-carcinoma sequence.
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Three categories of genes are involved in colorectal carcinogenesis: tumour- 
suppressor genes (e.g. APC, p53 and p i6), oncogenes (e.g. K-Ras) and DNA repair 
genes (e.g. MSH2, MLH1, PMS2)(Jo and Chung, 2005). Tumour suppressor genes 
inhibit cellular growth stimulatory pathways and classically require both alleles to 
be mutated before gene function is compromised. Some tumour suppressor genes 
exhibit a dominant negative effect where a single mutated allele leads to abnormal 
gene function. P53 is an example. The dominant negative effect arises because the 
functional p53 protein is tetrameric and a single mutant allele will give rise to 
abnormal proteins that are incorporated into the protein complex potentially 
impairing function. Oncogenes promote cellular growth and proliferation pathways 
and gene function is compromised by mutation in a single allele. DNA repair genes 
serve to maintain the integrity of the genome. DNA damage due to various 
genotoxic mechanisms and replication errors can lead to genetic instability and a 
“mutator phenotype” manifest by an increased mutation rate and mutation 
accumulation.
Clustering of CRC within families has long been recognised and syndromes with a 
very high risk of developing CRC have been identified. The conditions familial 
adenomatous polyposis (FAP) and hereditary non-polyposis colon cancer 
(HNPCC), in which the development of CRC is virtually inevitable, were identified 
as autosomal dominant conditions on the basis of family studies before the 
molecular pathology was elucidated.
Although hereditary CRC accounts for a small proportion of the total number of 
CRC cases, identification of the causative gene defects has lead to a greater 
understanding and provides a useful model of the molecular pathology of sporadic 
CRC.
1.1.11.1 Familial CRC.
Familial CRC can be divided into those tumours that arise as a result of high 
penetrance susceptibility genes and those that are due to low penetrance 
susceptibility genes. The former include HNPCC and FAP and are considered the 
hereditary CRCs. In the latter the precise genetics have not been elucidated but are 
characterised by multiple members of the same family being affected by CRC with 
an increased risk of developing CRC in unaffected members (Abdel-Rahman and 
Peltomaki, 2004, Kwak and Chung, 2007).
Hereditary CRC arises as a result of germ line mutations in key regulatory tumour 
suppressor or mismatch repair (MMR) genes. The majority are autosomal dominant 
conditions and therefore offspring of carriers have a 50% chance of inheriting the 
risk genes. Carriers have a germ line mutation in one allele and require mutation of 
the second allele to acquire the pathological phenotype (Knudson’s “two-hit 
hypothesis”(Knudson, 1971)). HNPCC and FAP are the commonest forms of 
inherited CRC and carry a very high risk. Other inherited conditions are also 
recognised that have an increased risk of developing CRC (Table 1.6). All of the 
inherited forms of CRC also carry an increased risk of extra-colonic malignancies, 
demonstrating that all the cells in the body have the germ line mutations and so are 
vulnerable. There is a predilection for the colon, however.
Syndrome Affected
Genes
Risk of 
CRC
Inheritance Age Extra-colonic
tumours
FAP APC 100% AD Late Duodenal,desmoid,
30s osteomas, thyroid,
brain
Attenuated APC >80% AD Mid Duodenal
FAP 50s
HNPCC MLH1, 80% AD Mid Uterus, ovary,
MSH2, 40s stomach, kidney,
MSH6 urinary tract,
biliary, small
intestine, skin
M YH MYH -100% AR Early
polyposis 50s
PJS STK11 40% AD Mid Uterus, breast,
(LKB1) 40s lungs, pancreas,
gallbladder
JPC SMAD4, 10-40% AD Mid Stomach,
BMPR1A 30s duodenum
Table 1.6: Hereditary CRC syndromes. (FAP - familial adenomatous polyposis, HNPCC - 
hereditary non-polyposis colon cancer, PJS - Peutz-Jegher’s syndrome, JPC - juvenile 
polyposis coli, HPS - hyperplastic polyposis syndrome).
Syndrome Affected
Genes
Risk
of
CRC
Inheritance Age Extra-colonic
tumours
Bloom’s
syndrome
BLM 8% AR Early
30s
Leukaemia, 
lymphoma, ENT 
tumours, ovarian, 
breast, upper GIT
I1307K APC  
polymorphism
APC 8-11% AD >60
Table 1.6 (continued): Hereditary CRC syndromes. (FAP - familial adenomatous polyposis, 
HNPCC - hereditary non-polyposis colon cancer, PJS - Peutz-Jegher’s syndrome, JPC - 
juvenile polyposis coli, HPS - hyperplastic polyposis syndrome).
1.1.11.2 Familial Adenomatous Polyposis (FAP).
FAP is manifested by the development of hundreds to thousands of colonic 
adenomatous polyps, starting in adolescence, with inevitable development of 
adenocarcinoma by the age of forty. FAP is a highly penetrant autosomal dominant 
disease, caused by germ line mutations of the adenomatous polyposis coli {APC) 
gene located on chromosome 5q21 (Merg et al., 2005a, Lipton and Tomlinson, 
2006, Maple and Boardman, 2006, Doxey et al., 2005). The condition is associated 
with various extra colonic tumours (Table 1.7) and individuals with FAP require 
screening for these conditions as part of their management. Indeed, as modem 
treatment has greatly reduced the mortality from CRC in FAP, these other tumours, 
particularly the upper gastrointestinal and desmoid tumours, are becoming more 
prevalent in FAP (Merg et al., 2005a, Galiatsatos and Foulkes, 2006).
Site Lifetime risk (%)
Desmoid 15
Duodenum 3-5
Thyroid 2
Brain 2
Ampullary 1.7
Pancreas 1.7
Hepatoblastoma 1.6
Gastric 0.6
Table 1.7: Extra colonic tumours associated with FAP.
FAP is diagnosed by the presence of a hundred or more adenomatous colorectal 
polyps at endoscopy (Jarvinen, 2004). Diagnosis should be followed by screening 
for associated tumours, establishing any family history of hereditary CRC and 
genotyping for APC mutations. Offspring of known APC mutation carriers should 
be genotyped as half will inherit the mutation, and those that are found to be 
carriers should be endoscopically screened from early adolescence (Jarvinen, 2004, 
Galiatsatos and Foulkes, 2006, Maple and Boardman, 2006). Colectomy is the 
treatment of choice, either due to the presence of polyposis, symptomatic polyposis 
or prophylactically at an appropriate time in screened APC mutation carriers (Maple 
and Boardman, 2006, Galiatsatos and Foulkes, 2006, Jarvinen, 2004).
Many different mutations of the APC gene have been demonstrated in APC, but the 
majority give rise to a truncated, dysfunctional protein product (Doxey et al., 2005). 
The APC gene primary function is in cellular adhesion and migration (Galiatsatos 
and Foulkes, 2006). It has a fundamental tumour suppressor role in antagonising the 
Wingless/Wnt cellular signalling pathway via its interaction with P-catenin (Merg et 
al., 2005a, Lipton and Tomlinson, 2006, Doxey et al., 2005). APC mutations lead to 
impaired P-catenin degradation which thus accumulates within the cytoplasm and
activates the Wnt signalling pathway, leading to increased cell proliferation (Doxey 
et al., 2005) . APC is also involved with several other cellular proteins including a- 
catenin, GSK3P, axin, (Wnt signalling proteins) and conductin, tubulin, EB1 
(microtubule and cell migration proteins) and hDLG (cell adhesion and motility) 
and has roles in cell cycle control by regulating Go/Gi > S phase progression, 
apoptosis and neuronal differentiation (Hanson and Miller, 2005, Galiatsatos and 
Foulkes, 2006).
Therefore APC  mutations can lead to increased cellular proliferation, decreased 
apoptosis, chromosomal instability and impaired cell cycle control, all important 
factors in carcinogenesis.
Disease severity in FAP has been shown to be linked to the position of mutations in 
the APC gene, so-called genotype-phenotype correlations, and demonstrates how 
the effect of mutation on gene function can be dependent on where in the genome 
the mutation occurs (Galiatsatos and Foulkes, 2006, Merg et al., 2005a). Codon 
1309 APC mutations lead to an accelerated form of FAP where polyposis occurs at 
an earlier age, is more florid and malignant change is more rapid. Mutations 
between codons 976-1067 have a high incidence of duodenal tumours and 
mutations between codons 543-1309 are associated with congenital hypertrophy of 
retinal pigment epithelium (CHRPE), a condition leading to pigmented retinal 
lesions that occasionally can give rise to malignant transformation(Sheilds et al., 
2001) and as they are congenital they are an important, early sign in APC mutation 
carriers. Mutations that occur at the extreme ends of the APC gene lead to 
“attenuated FAP”, manifest by fewer polyps, later age of onset and lower risk of 
CRC.
APC gene function has also been found to be impaired by single nucleotide 
polymorphisms (SNP). A thymine to adenine transversion at nucleotide 3920 (3920 
T>A) leads to isoleucine being substituted with lysine at codon 1307 (I1307K)
(Laken et al., 1997). This missense mutation leads to an increased risk of 
developing adenomas and CRC, but not the polyposis as seen in classical FAP. The 
SNP is carried by 6% of Ashkenazi Jews and in around 28% of Ashkenazim with a 
family history of CRC.
1.1.11.3 Hereditary Non-polyposis Colorectal Cancer (HNPCC).
HNPCC (also called Lynch syndrome) is manifest by the development of 
proximally sited CRC at a young age and is due to autosomal dominantly inherited 
mutations in MMR genes. The tumours develop from solitary polyps, in contrast to 
FAP (Jarvinen, 2004). The life time risk of developing CRC is in the order of 75- 
80%. The condition is associated with other, extra-colonic tumours and multiple 
family members are affected with either CRC or the other related tumours 
(Tablel.8).
Site Frequency (%)
Colon 80
Endometrium 40
Stomach 15
Ovary 12
Urothelium 5
Other (small bowel, pancreas, brain) <5
Table 1.8: Cancers associated with HNPCC.
Clinical diagnosis is achieved when cases fulfil the Amsterdam criteria (Table 1.9) 
and those cases should be referred for genetic testing.
1. Three (or more) family members with HNPCC related cancer; one a first degree 
relative of the other two.
2. HNPCC cancer in at least two generations.
3. At least one individual diagnosed before 50 years of age.
4. FAP excluded.
Table 1.9: Amsterdam criteria for clinical definition of HNPCC(Vasen et al., 1999).
Those familial cancers that do not fulfil the Amsterdam criteria are evaluated 
according to the revised Bethesda guidelines (Table 1.10) and undergo genetic 
testing accordingly.
1. CRC diagnosed at less than 50 years of age.
2. Presence of synchronous or metachronous HNPCC related tumours regardless of 
age.
3. Microsatellite instability “high” CRC tumours in individuals less than 60 years of 
age.
4. CRC diagnosed in one or more 1st degree relatives with an HNPCC- related 
tumour, with one of the tumours diagnosed under the age of 50 years.
5. CRC diagnosed in two or more 1st or 2nd degree relatives with HNPCC-related 
tumours, regardless of age.
Table 1.10: Revised Bethesda guidelines.
Individuals who satisfy either the Amsterdam criteria or the Bethesda guidelines 
should be genetically tested to determine whether they carry germ line mutations in 
any of the DNA mismatch-repair (MMR) genes (Table 1.11).
Gene Locus Percentage of HNPCC
MHS2 2p22-p21 60%
MLHI 3p21.3 30%
MSH6 2pl6 5%
PMS2 7p22 minimal
PMS1 2q31-q33 minimal
TFGBR2 3p22 minimal
MLH3 14q24.3 Minimal
Table 1.11: MMR genes mutated in HNPCC.
MMR genes function to correct errors of base-base mismatch and insertion-deletion 
loops that form during DNA replication. Base-base mismatches lead to single base 
substitutions and insertion-deletion loops involve gains or losses of short repetitive 
DNA nucleotide units (microsatellites) a phenomenon known as microsatellite 
instability (MSI). Although most microsatellite sequences are found within non­
coding genomic regions certain growth regulatory genes have DNA microsatellites 
within their coding regions. Such genes include the transforming growth factor-f 
receptor II  and insulin-like growth factor II  receptor genes, the E2F transcription 
factor 4 gene, the p53 regulated proapoptotic BAX (BCL2-associated X  protein) 
gene and the MMR genes hMSH3 and hMSH6 (Jo and Chung, 2005). Loss of MMR 
function leads to accumulation of mutations in these genes and hence loss of 
cellular growth regulation, the hall-mark of cancer development. Defective MMR 
function leads to 100 or 1000 fold mutation rates in affected cells and so individuals 
who possess a germ-line mutation of an MMR gene are at great risk of 
accumulating mutations and thus developing cancer at a younger age than the 
general population (Abdel-Rahman and Peltomaki, 2004).
HNPCC is managed by aggressive screening with resection of identified high grade 
dysplastic lesions or carcinomas.
1.1.11.4 MYH  Polyposis.
Individuals with FAP phenotype have been discovered who do not harbour an APC 
mutation. Genetic analysis has shown that mutations of the E. coli mutY homologue 
gene (.MYH) at locus Ip34.3-p32.1 are responsible. Unlike the other inherited CRC 
genes the MYH  gene has a recessive mode of inheritance, however mono- and bi- 
allelic earners have an increased risk of CRC (Doxey et al., 2005). MYH  is a base 
excision repair gene involved in repairing oxidative DNA damage due to reactive 
oxygen species (Doxey et al., 2005, Lipton and Tomlinson, 2006, Galiatsatos and 
Foulkes, 2006). Oxidation of guanine (G) nucleotides leads to the formation of 8- 
oxo-7, 8-dihydro2’deoxyguanosine (8-oxoG) which mispairs with adenine (A) 
rather than cytosine (C). This then leads to G:C to T:A transversion mutations in the 
daughter strand during DNA replication. MYH scans the daughter strands for such 
mutations and excises them. Losses of MYH  function due to mutations leads to 
preservation of G:C to T:A transversions. When such mutations occur in APC, for 
example, polyps and carcinoma result.
85% cases of M7//-associated polyposis are due to 2 mutations; tyrosine 165 to 
cystine (Y165C) and glycine 382 to aspartine (G382D).
1.1.11.5 Bloom’s Syndrome.
Bloom’s syndrome is a very rare condition associated with multiple site cancers (Jo 
and Chung, 2005). There is a characteristic phenotype of short stature, 
photosensitivity, variable skin pigmentation, diabetes and infertility.
The syndrome is due to germ line mutations in the RecQ helicase gene family 
member, BLM, located at chromosome 15q26.1. BLM helicase functions to re start 
DNA replication at arrested or collapsed replication forks (Kaneko et al., 2004).
BLM  mutations lead to chromosomal instability due to destabilization of enzymes 
involved in DNA replication and repair (Ellis et al., 1995) and hence tumorigenesis. 
Like MYH  polyposis, BLM is recessively inherited.
1.1.11.6 Hamartomatous Polyposis Syndromes.
CRC arising from hamartomatous polyps is seen in the autosomal dominant Peutz- 
Jeghers (PJS) and Juvenile polyposis (JPS) syndromes (Jo and Chung, 2005, Lipton 
and Tomlinson, 2006, Jarvinen, 2004).
PJS is due to mutations of the tumour suppressor gene STK 11 (previously named 
LKB 1) located at chromosome 19pl3.3. STK 11 is a serine-threonine kinase with 
many functions, including p53-dependent apoptosis regulation (Karuman et al., 
2001), cell cycle arrest (Tianen et al., 2002) and maintaining cellular polarity 
(Martin and Johnston, 2003).
JPS is caused by mutations in the mothers against decapentaplegic, Drosophila, 
homolog of, 4 (SMAD4) gene on chromosome 18q21.1 or bone morphogenetic 
protein receptor type 1A (BMPR1A) gene on chromosome 10q22.3. SMAD4 is 
involved in the intracellular transforming growth factor p (TGF- P) signalling 
pathway (Zhou et al., 1998). BMPR1A is a member of the TGF- p super family and 
is involved in a SMAD4 dependent intracellular signalling and transcription 
regulation bone morphogenetic protein (BMP) pathway (Merg et al., 2005b). 
Mutations of SMAD4 and BMPR1A lead to increased cell proliferation and 
dysplasia, and hence CRC.
1.1.12 Sporadic CRC.
The majority of CRC arise spontaneously, that is, in individuals with no obvious 
genetic or familial risk factors. The hereditary CRCs, although accounting for only
a small proportion of CRC cases, illustrate some of the genetic mechanisms 
involved in sporadic colorectal carcinogenesis, for example the APC and the MMR 
genes have been shown to be involved in sporadic CRC.
As previously stated, CRC (and indeed all cancers) arise due to accumulation of 
mutations in key regulatory genes involved in cell cycle control and growth, 
apoptosis, DNA surveillance and repair, and genes that are important for cancer 
invasion and metastasis such as those involved in cell adhesion, migration, 
proteolysis and angiogenesis. Also involved are epigenetic mechanisms of DNA 
methylation and histone modification. Analysis of the molecular pathology of CRC 
demonstrates that carcinogenesis follows various genetic pathways (Takayama et 
al., 2006).
1.1.12.1 Chromosomal Instability Pathway.
85% of sporadic CRC tumour cells show aneuploidy (abnormal quantities of DNA) 
as a result of chromosomal losses and gains (Terdiman, 2000). Progression along 
the adenoma-carcinoma sequence is mirrored by chromosomal losses on 5q (APC), 
17p (TP53) and 18q (DCC/SMAD) (Vogelstein et al., 1988).
APC (already discussed above) mutations occur early in adenoma development and 
may be the initiating event in colorectal carcinogenesis (Heinen et al., 2002).
K-Ras mutations also occur during the adenomatous stage and are found with 
increasing frequency with increasing adenoma size and dysplasia (Howe and 
Guillem, 1997). K-Ras controls various downstream genes involved in normal 
cellular proliferation and differentiation (Leslie et al., 2002). K-Ras mutation leads 
to activation and confers a growth advantage to the cell.
The transition of adenomas to carcinomas is thought to be due to mutations in TP53 
(Dietel, 1998). TP53 mutations are found in most CRC tumours and, indeed, in
many other cancers. It has been termed “the guardian of the genome” (Navaratnam 
et al., 1999) as it has a wide range of functions involved in cell cycle control, DNA 
repair and apoptosis via its control of a large number of genes. CRCs displaying 
TP53 mutations have been shown to carry a worse prognosis than those where TP53 
function is preserved (Pricolo et al., 1997).
Most advanced and invasive tumours show chromosome 18q losses. DCC (Deleted 
in Colorectal Cancer) was originally thought to be the candidate for these loses, but 
this has not been supported by subsequent research. (Leslie et al., 2002, Takayama 
et al., 2006). SMAD genes are also found at this locus and are involved in the TGF- 
P cell signalling pathway which itself is involved in cell growth, differentiation, 
matrix production and apoptosis. SMAD2 and SMAD4 mutations lead to 
inactivation of the TGF-p cell signalling pathway (Fukushima and Takenoshita, 
2001, Terdiman, 2000).
Table 1.12 summarises the genes involved in the chromosomal instability pathway.
Gene Chromosome Function
Tumour suppressor genes
APC 5q21 Inhibition of cell growth.
TP53 17pl2 G1 cell cycle arrest/apoptosis.
SMAD 18q21 P15/p21 induced growth arrest.
DCC 18q21 Cell-cell interaction/apoptosis
Oncogenes
K-Ras 12pl2 Growth promotion
P-catenin 31q21
Cell adhesion/ proliferative 
signalling
Table 1.12: Genes involved in the chromosomal instability pathway.
1.1.12.2 Microsatellite Instability Pathway.
MSI has already been discussed in the context of HNPCC above, however MSI has 
also been recognised in sporadic CRC where up to 30% cases are MSI positive 
(Grogan et al., 1996). MSI positive CRC tumours can be classified as low- or high- 
frequency MSI (MSI-L or MSI-H). MSI-L tumours display only one to two altered 
loci and are associated with APC, TP53 and K-Ras mutations whereas MSI-H 
tumours have three or more altered loci and have fewer APC, TP53 etc mutations, 
indicating that MSI can lead to the malignant phenotype without chromosomal 
instability and that in some tumours both pathways contribute (Baba, 1997). Table
1.13 summarises the genes involved in the microsatellite instability pathway.
Gene Chromosome Function
TGF-P Receptor II 3p22 Cell growth inhibition
BAX 19ql3.3-ql3.4 Apoptosis induction
IGF-II receptor 6q26 Growth promotion
hMSH6 2pl6 MMR
hMSH3 5q ll-q l2 MMR
PTEN 10q23.32 Cell growth inhibition
E2F-4 16q22.1 G1 cell cycle arrest
Table 1.13: Genes involved in the microsatellite instability pathway.
1.1.12.3 TGF-p /SMAD Signalling Pathway.
The TGF-p/SMAD pathway has been described previously in the context of the 
hereditary hamartomatous polyposis syndromes. TGF-PRII complexes with TGF- 
pRI as a result of TGF-P binding. This complex phosphorylates SMAD2 which
forms a complex with SMAD4 that induces p i5 and p21 within the cell nucleus. 
P I5 and p21 are Cdk inhibitors and function to arrest cell growth (Takayama et al., 
2006). Up to 25% of sporadic CRC tumours have been shown to have inactivating 
SMAD4 mutations, and around 6% have SMAD2 mutations. TGF-flRII mutations 
are common in MSI positive tumours, and in those MSI positive tumours without 
TGF-pRII mutations, IGF-II mutations are frequently found. TGF-pRII and SMAD 
mutations are associated with adenoma-carcinoma transition. The TGF-p signalling 
pathway also interacts with the Wnt pathway to promote CRC carcinogenesis, 
illustrating how the various molecular pathways interact with each other to produce 
the malignant phenotype.
1.1.12.4 Genetics of Invasion and Metastasis.
Invasion and the ability to metastasise is the hallmark of malignancy. Many 
processes are involved including digestion of the extra-cellular matrix (ECM), cell­
cell adhesion, angiogenesis, migration and evading the immune system that allow 
for tumour cells to invade tissues adjacent to their tissue of origin and to metastasise 
to distant sites. CRC tumour cells have been shown to express genes that confer 
these characteristic upon them (Table 1.14) (Takayama et al., 2006, Kountouras et 
al., 2000).
Gene Chromosome Function
MMP-1,-8,-13 
MMP-2, -9
MMP-3
MMP-7
TIMP-1
uPAR
Integrins
Cadherins
CD44
CEA
VEGF
PD-ECGF
Tumour Necrosis
Receptor Family
CXCR4
Drg-1
c-Met
Proteolysis genes 
1 Iq21-q23 Collagen I, II, III, IV, VI, IX, X and XI digestion
16q 13, Gelatins and collagen IV digestion
20ql 1.2-ql3.1
I lq23 Fibronectin and laminin digestion
Ilq21-q22 Fibronectin, laminin, collagen IV and
proteoglycans digestion 
Xpl 1.3- MMP inhibition
pi 1.23
19q 13 Plasminogen activation regulation
Adhesion genes
Extra-cellular matrix component binding 
Cell-cell adhesion
II pter-p 13 Matrix adhesion lymphocyte activation
19ql3.2 Kupffer cell binding
Angiogenesis genes 
6pl2 Mitogen for vascular endothelial cells
22ql2.32-qter Angiogenesis 
Miscellaneous genes 
Factor Apoptosis regulation
2q21 CRC cell migration/metastasis
Cell differentiation
Hepatocyte growth factor receptor, enhances 
metastatic growth
Table 1.14: Genes involved in CRC invasion and metastasis.
1.1.12.5 Epigenetics of CRC.
Epigenetics refers to heritable processes distinct from DNA sequence modification 
that determine gene expression such as histone modification, DNA methylation, and 
RNA modifications (Wong et al., 2007). Histones form the core of chromosomes 
around which DNA is wrapped and are subject to reversible modifications that have 
a role in regulating gene expression. DNA methylation is involved in regulating 
differential gene expression such as X chromosome silencing, age related and tissue 
specific gene expression. Abnormalities in epigenetic mechanisms have been shown 
to have a role in carcinogenesis and have been demonstrated in CRC (Kondo and 
Issa, 2004). Both hypo- and hypermethylation of DNA have been implicated in 
carcinogenesis. Hypomethylation is thought to increase chromosomal instability. 
Hypermethylation of promoter region of various tumour suppressor, MMR and cell- 
cycle regulatory genes leads to their silencing (Wong et al., 2007). Epigenetic 
abnormalities tend to occur early in CRC development, and are even seen in normal 
epithelium, and so may serve as a marker for CRC risk.
The development of the understanding of the genetic mechanisms involved in CRC 
has provided a great insight into the molecular pathology of cancer globally. It has 
also led to the understanding that tumour biology and behaviour is related to tumour 
genotype. Genetic staging of tumours may provide more accurate prognostic 
information than traditional pathological staging, and may also allow better 
prediction of therapeutic response to adjuvant therapies.
1.1.12.6 Genetic Predisposition to Sporadic CRC.
The hereditary CRCs show how highly penetrant genetic mutations greatly increase 
the risk of developing CRC and the genetic pathways described above shows how
the accumulation of mutations drives tumour development. However exactly how 
sporadic CRC is initiated is not well understood. The environmental risks have been 
discussed above and it is of considerable interest whether there are heritable genetic 
factors that increase the risk of developing sporadic CRC. Knowledge of such genes 
would be of benefit in allowing more accurate risk stratification than is currently 
possible on the basis of family history. It is clear that similar environmental 
exposure in different individuals does not necessarily result in cancer in all those 
individuals, therefore there must be intrinsic, and most probably genetic, factors 
modulating environmental risk.
There has been considerable research into the role of low penetrance genetic 
variants on CRC risk and although there are controversies and difficulties with such 
studies there has been some progress in identifying such risk factors (Kemp et al., 
2004). Single nucleotide polymorphisms (SNPs) are thought to be the most likely 
candidates for influencing risk and have been subject to intense study. Disease-gene 
association studies have identified yfPC-I1307K, HRAS1-VNTR, and MTHFR 
polymorphisms as influencing the increased risk of CRC (Houlston and Tomlinson,
2001) however the effect is modest. Studies have also looked at the effect of gene- 
gene and gene-environment interactions on CRC risk (Goodman et al., 2006, Webb 
et al., 2006). The role of SNPs in CRC is discussed in greater detail later.
1.1.13 Treatment.
Treating CRC has one of two aims depending on the stage of disease at 
presentation. Those tumours that are at an early stage, without evidence of local 
invasion or distant metastases, are potentially curable with radical surgical excision. 
Those tumours that have invaded local tissues or that have metastasised to distant 
organs are considered incurable and their treatment is palliative. Curative treatment
depends of completely removing all malignant tissue with a wide margin of normal 
tissue by surgical excision. Patients who have had excised tumours that are shown 
on histological examination to have lymph node metastases are offered 
chemotherapy as this treatment has been shown to prolong survival. There is 
currently increasing interest and enthusiasm for excising solitary hepatic 
metastases, both those found at presentation and those that develop post curative 
surgery. For rectal cancers radiotherapy has a role, both before surgery where it 
may help to reduce the size of tumours in order to render them excisable and post 
operatively if  there are found to be involved lymph nodes or margins.
Palliative treatment involves controlling the symptoms of CRC. This may involve 
surgery to bypass obstructing tumours or chemotherapy to try to slow the 
progression of metastatic disease.
At present the only hope of cure from CRC rests on excising early stage tumours. In 
order to reduce the mortality from CRC it is necessary to increase the proportion of 
cases that are diagnosed at stage I or II. However these stages tend to be relatively 
asymptomatic, therefore screening may be the only way to detect these tumours and 
so achieve lower mortality from CRC.
1.1.14 Screening.
In 1968 the World Health Organization published screening guidelines and 
specified the criteria for screening programs (Wilson and Junger, 1968):
1. The condition should be an important health problem.
2. There should be a treatment for the condition.
3. Facilities for diagnosis and treatment should be available.
4. There should be a latent stage of the disease.
5. There should be a test or examination for the condition.
6. The test should be acceptable to the population.
7. The natural history of the disease should be adequately understood.
8. There should be an agreed policy on who to treat.
9. The total cost of finding a case should be economically balanced in 
relation to medical expenditure as a whole.
10. Case-finding should be a continuous process, not just a "once and for 
all" project.
In 2003 the UK National Screening Committee developed similar criteria for 
screening. Although screening programmes are far from controversial, screening 
for breast and cervical cancers have led to a reduction in disease related mortality 
and disease incidence respectively (Blanks et al., 2000, Sasieni et al., 2003). CRC 
would seem for screening and indeed screening has been shown to reduce the risk 
of dying from CRC (Hewitson et al., 2007).
CRC screening should be considered in terms of high risk groups screening and 
population screening. High risk groups include the hereditary and familial CRCs; 
patients who have had a CRC or high risk adenoma resected and patients with long 
standing inflammatory bowel disease. Guidelines have been published with regard 
to these groups in order to aid clinicians (Dunlop, 2002a, Dunlop, 2002b, 
Scholefield and Steele, 2002, Atkin and Saunders, 2002, Eaden and Mayberry, 
2002).
Population screening involves inviting asymptomatic individuals from the general 
population to under go a screening test. In terms of CRC screening can be 
performed using either radiological or endoscopic imaging or by faecal occult blood 
(FOB) detection, tests which have been shown to be adequately sensitive and 
specific. Currently the National Health Service is rolling out a bowel cancer
screening programme in England using FOB detection testing 
(www.cancerscreening.nhs.uk/bowel). All men and women aged between 60 and 69 
will be invited to be screened every two years. It is anticipated that two percent of 
those screened will have an abnormal test and these individuals will then be referred 
for further investigation.
1.1.14.1 Genetic Screening.
Genetic screening for sporadic CRC depends on a comprehensive knowledge of the 
genetic factors that influence the risk of individuals developing CRC. This 
knowledge would allow an individual’s genetic risk to be established and so inform 
whether targeted screening and behaviour modification would be appropriate (Bum 
et al., 2001). To this end there has been a huge drive to both identify susceptibility 
genes and develop the technology to allow rapid and efficient genotyping (Collins 
et al., 1998b, Stremmel et al., 2002). However, in contrast to the “Mendelian 
CRCs”, FAP and HNPCC, the identification and disease risk determination of the 
genes is far more complex and has necessarily led to the development of new 
epidemiological methodologies (2007, Goodman et al., 2006, Harkin, 2006). 
Although several genes have been shown to be associated with CRC there is as yet 
insufficient information to be able to determine the overall effect on the risk of 
developing CRC and so determining individual CRC risk profiles. Therefore there 
are currently no genetic screening programmes for CRC, other than those for the 
Mendelian CRC syndromes.
1.1.15 Summary.
CRC is an important public health issue leading to many deaths each year. Current 
management depends on diagnosing symptomatic individuals or screening high risk 
individuals with inherited CRC syndromes. This approach results in a high 
proportion of sporadic CRC cases being diagnosed at an advanced stage and as a 
consequence mortality rates remain high. Population screening for CRC would lead 
to earlier diagnosis and should help to reduce mortality, as has been seen with 
breast cancer. Screening programmes being developed are based on occult bleeding 
tests or endoscopic surveillance.
Although the genetics of the inherited CRC syndromes and the adenoma-carcinoma 
sequence are well understood, low penetrance genetic susceptibility factors are less 
well understood and so population genetic screening has yet to be realised. 
However as knowledge of this area increases and technologies for rapid genotyping 
improve genetic screening for CRC susceptibility will become a reality.
1.2 SINGLE NUCLEOTIDE POLYMORPHISMS.
1.2.1 Introduction.
Single nucleotide polymorphisms (SNPs) are the most abundant form of genetic 
variation accounting for about 90% of sequence differences in the human genome 
(Wang et ah, 1998, Wang and Moult, 2001). 85% of SNPs are common to all 
human populations and arose within the human genome after speciation but before 
the emergence of different populations, and so the majority of human genetic 
variance occurs within rather than between populations. SNPs are found scattered 
throughout the genome and account for several million single base differences 
between individuals. Coding SNPs result in around 100 000 amino acid differences 
in our proteomes.
SNPs may hold the key to understanding the genetics of common complex diseases 
such as diabetes, heart disease and cancer (Collins et al., 1998a). Common complex 
diseases are thought to arise due to both gene-environment and gene-gene 
interactions where variations in multiple interacting polymorphic genes modulate 
the risk of developing disease states (Kirk et al., 2002, Rueff et al., 2002). The role 
of SNPs as research tools has been shown to be important in the investigation of the 
molecular biology of common complex human diseases and a major part of the 
Human Genome Project is the cataloguing of SNPs (Risch and Merikangas, 1996, 
Collins et al., 1997, Wang et al., 1998). The power of SNPs lies in their use as 
genetic markers for identifying disease genes by association studies of candidate 
genes (Collins et al., 1998b) and in their suitability for automated gene 
identification techniques using micro array technology, where multiple candidate 
SNPs can be screened simultaneously (Friend and Stoughton, 2002). Knowledge of
an individual’s SNP profile may allow disease susceptibility assessment and direct 
tailored screening and prevention strategies for at risk diseases (Brown et al., 2003).
1.2.2 Definition.
SNPs can be defined as “Single base pair positions in genomic DNA at which 
different sequence alternatives (alleles) exist in normal individuals in some 
population(s), wherein the least frequent allele has an abundance of 1% or greater” 
(Brookes, 1999).
1.2.3 Classification.
SNPs are classified as transitions, where a pyrimidine (Cytosine or Thymine) is 
substituted by a pyrimidine or a purine (Adenine or Guanine) is substituted by a 
purine, or transversions, substitution of a pyrimidine by a purine or vice versa.
Two thirds of SNPs are represented by the Cytosine to Thymine transition a 
disproportionately high frequency due the high frequency of 5-methlycytosine 
deamination reactions that occur at CpG dinucleotides (Brookes, 1999).
1.2.4 SNP genomic location.
In predicting the effects of SNPs on gene function knowledge of the location of the 
SNP in the genome is important and whether the SNP is transcribed and translated. 
SNPs in coding regions (cSNPs) and regulatory regions are most likely to affect 
gene function as these have the greatest potential to lead to altered protein structure 
(and hence function) or to variations in gene expression (Wang and Moult, 2001).
1.2.4.1 Intronic SNPs.
Introns are non-coding sections of DNA that are not translated into the protein 
product. Introns are transcribed with exons but are removed by post-transcriptional 
mRNA modification by a process know as splicing. Splicing takes place at ‘splice 
sites’ at the exon-intron boundaries. Correct splicing is essential for gene 
expression. Introns may also be involved in regulating gene expression.
SNPs that fall within introns may activate cryptic splice sites or may eliminate 
splice sites, leading to alternative genomic splicing and gene transcription, or may 
interfere with gene expression. Either mechanism may lead to gene dysfunction and 
disease.
Examples of diseases caused by intronic mutations include some forms of 
congenital adrenal hyperplasia (Higashi et al., 1988, Steinberg and Adams, 1982), 
most of the beta thalassaemias (Steinberg and Adams, 1982) and an autosomal 
dominant form of isolated growth hormone deficiency (McCarthy and Phillips, 
1998).
1.2.4.2 Exonic SNPs.
Exons are coding or non-coding (untranslated) DNA sequences that occur between 
introns. The translation of the coding sequences gives rise to the protein product of 
genes.
1.2.4.2.1 Coding SNPs.
SNPs that occur with in the coding DNA can give rise to various mutations:
1.2.4.2.2 Synonymous (silent) mutations.
These are the most frequent SNP mutations in coding DNA. The mutation is neutral 
and involves nucleotide base substitution that creates a codon that codes for the 
same amino acid as the codon containing the wild type polymorphism. They tend to 
occur at the 3rd base position of the codon and can be referred to as “3rd base 
wobble”.
1.2.4.2.3 Nonsense mutations.
These non-synonymous nucleotide substitutions create a stop codon from an amino 
acid codon leading to premature ending of translation, and therefore can profoundly 
interfere with gene function. Because of this they are under great selection pressure 
and are rare.
1.2.4.2.4 Missense mutations.
These are also non-synonymous nucleotide substitutions that create codons for 
different amino acids than the wild type. They can be conservative, where the new 
amino acid is chemically similar to the wild type thus having little functional effect 
on the protein product, or non-conservative where the substituted amino acid is 
chemically distinct and can alter the protein product morphology thus interfering 
with its function. Missense SNPs account for half of all pathogenic genetic 
mutations (Wang and Moult, 2001).
1.2.4.3 Untranslated region SNPs.
Untranslated regions (UTRs) flank genomic exons at the 5’ and 3’ ends. They are 
transcribed to mRNA and assist in binding and stabilising ribosomes during 
translation.
The 3’ UTR has a key role in regulating, stabilising and localizing translation 
(Wickens et al., 1997, Day and Tuite, 1998, Siomi and Dreyfuss, 1997). SNPs in 
these regions could therefore interfere with the binding of ribosomes and other 
RNA binding proteins, thus interfering with gene function by modulating mRNA 
translation.
UTR SNPs may enhance or reduce gene function. It has been shown that a 3’ UTR 
SNP of the human dihydrofolate reductase gene is associated with enhanced gene 
expression (Goto et al., 2001).
1.2.5 Use of SNPs.
SNPs have three primary uses; candidate polymorphism testing, diagnostics and 
risk profiling and prediction of response to xenobiotics (Schork et al., 2000). 
Candidate polymorphism testing involves selecting polymorphisms that are 
potentially associated with diseases and performing case-control studies to test that 
association. Selecting polymorphisms requires a reasonable knowledge of a 
diseases molecular pathology in order to target the studies. For example it would be 
reasonable to study polymorphisms of cell cycle control genes in cancer studies, as 
loss of cell cycle control is fundamental to carcinogenesis. In these types of study 
the polymorphisms could be causally associated, where they lead to altered gene 
function and disease phenotype, or they may be in linkage disequilibrium with 
disease genes. There has been a surge in these types of studies in the past few years
and in order to facilitate this interest in candidate polymorphism disease association 
there have been determined efforts to catalogue human SNPs (Collins et al., 1997, 
Wang et al., 1998, Collins et al., 1998b).
If SNPs are found to be associated with diseases then the risk of developing the 
disease can be attributed to either individual SNPs, SNP haplotypes or to an 
individual’s SNP profile. Genetic profiling could be used for targeted disease 
screening, to ameliorate disease risk by adjusting environmental and life-style risk 
factors and to tailor disease management.
One of the potential phenotypic effects of SNPs is variation in drug metabolism 
leading to variation in response to the same drug between individuals. Knowledge 
of the variation of response of individuals to xenobiotics due to SNPs can be 
applied to drug design and knowledge of an individual’s SNP profile could lead to 
individualised pharmacotherapy. This may be particularly applicable to variations 
in response of tumours to chemotherapy.
1.2.6 SNPs and carcinogenesis.
Whilst some cancers, for example familial adenomatous polyposis and familial 
retinoblastoma, are known to arise due to high-penetrance dominant genes, the 
majority of common cancers, such as lung, breast, colorectal and skin cancer, arise 
sporadically. These cancers, like other common complex diseases, are thought to be 
caused by the interaction of multiple low-penetrance genes both with themselves 
and with the enviromnent to which the individual is exposed (Shields and Harris,
2000). SNPs are likely candidates for low-penetrance disease risk genes as they are 
so abundant and widespread throughout the genome. The risk that individual SNPs 
confer to an individual depends on the attributable risk of the SNP itself, the 
presence of other genes influencing disease and the environmental risks to which
the person is exposed. Therefore determining genetic risk is a complex process that 
must take into account all these factors. However, SNPs have been extensively 
studied with regard to cancer association, both due to the biological plausibility of 
their being the reason for inter-individual variation in cancer risk and due to their 
accessibility as they are abundant and easy to detect (Shields and Harris, 2000, 
Imyanitov et al., 2004, Houlston and Peto, 2004).
Research efforts at establishing SNP-cancer association have concentrated on the 
classes of genes known to be involved in carcinogenesis; xenobiotic metabolizers, 
hormone metabolizers, DNA repair genes, cell cycle control genes, angiogenesis 
genes, as well as with the oncogenes and tumour suppressor genes known to be 
involved in mutagenesis (Imyanitov et al., 2004).
Xenobiotic metabolizers are those enzymes involved in the detoxification of 
environmental carcinogens. Examples of extensively studied polymorphic 
xenobiotic metabolizers considered likely to influence carcinogenesis include the 
glutathione-S-transferases (GSTM1, GSTT1, GSTP1, GSTM3), N- 
acetyltransferases (NAT1 and NAT2), and cytochromes (CYP2D6, CYP2E1 and 
CYP1A1) (Benhamou et al., 2002, Lower et al., 1979, Ayesh et al., 1984, Seidegard 
et al., 1986, Vineis et al., 2003, Vineis et al., 2001) . The results of such studies 
have, however, yielded modest odds ratios and not led to the genes being utilised 
for clinical predictive testing (Imyanitov et al., 2004).
Breast and prostate cancers are known to be endocrine related, meaning that 
circulating hormones (specifically steroid hormones in these cases) influence their 
growth. Therefore attention has been focused on the influence of polymorphic 
variations of steroid metabolizer genes on the development of these cancers 
(Mitrunen and Hirvonen, 2003, Nelson and Witte, 2002). Again the results of these 
studies have been disappointing.
Failure of DNA damage repair is known to be fundamental to the development of 
many cancers and many of the highly penetrant genes (TP53, BRCA1, MSH1, PMS1 
etc) predisposing to cancer are involved in DNA damage surveillance and repair. 
These genes have therefore been targeted for studying the effects of low penetrance 
polymorphic variations on cancer susceptibility (Berwick and Vineis, 2000).
1.2.7 SNPs and Colorectal cancer.
CRC has and continues to be an important subject for SNP studies. This is due to it 
being the third most common cancer, accounting for 30,000 new cases and 17,000 
deaths every year in the United Kingdom, and due to the fact that three quarters of 
those cases arise sporadically. Although the major environmental and genetic risk 
factors have been identified, it is clear that there is inter individual variation in 
disease susceptibility and that this variation is likely to be due to low penetrance 
genes, particularly SNPs (Kemp et al., 2004, Houlston and Tomlinson, 2001). 
Combined with the development in SNP technology allowing rapid identification of 
SNPs this has led to a large number of SNP-CRC association studies being 
performed with the aim of defining the risk of low penetrance genes in CRC and 
ultimately to be able to define an individual’s risk according to their genotype 
(Harkin, 2006).
Most of the studies so far have concentrated on SNPs in candidate genes that are 
likely, or known, to be involved in colorectal carcinogenesis; carcinogen 
metabolizers (CYP1A1, NAT1, NAT2, GSTM1, GSTT1, GSTP1, mEPHX), 
methylation enzymes (MTHFR, MTR), DNA repair genes (MMR genes), micro 
environmental modifiers (APOE, PLA2G2A), oncogenes and tumour suppressors 
(HRAS1, L-myc,TP53) (Mort et al., 2003, Jong et al., 2002, Houlston and 
Tomlinson, 2001). Pooled analysis of studies of 30 polymorphisms demonstrated an
increased risk of CRC associated with GSTT1, NAT2, HRAS1 and ALDH2 
polymorphisms; MTHFR, TP53 polymorphisms showed a decreased risk; TNF-a 
displayed both an increased and decreased risk with different alleles (Jong et al.,
2002). However the results of individual studies are inconsistent. A recent large 
study of 1467 SNPs demonstrated CRC risk associated with A kinase anchor 
protein 9 (AKAP9) M463I, ataxia telangiectasia mutated (ATM) F858L and 
P1054R, and methylenetetrahydrofolate reductase (MTHFR) A222V (Webb et al., 
2006). Polymorphism interaction analysis (PIA) has identified the GSTT1-02 SNP 
as a strong predictor of CRC and that the presence of p53 Arg72Pro or CASP8 
Asp302His SNPs in combination with the GSTT1-02 SNP modifies the CRC 
association (Goodman et al., 2006).
Although a great deal of work has been done looking at the relationships between 
SNPs and CRC, there is still insufficient data available to be able to use SNPs as a 
screening tool for CRC. Only with further research and a greater understanding of 
the role of SNPs and their influence on CRC risk will SNP screening become a 
reality. Integral to this work is to identify candidate CRC association SNPs.
Reprimo and p53R2 are genes involved in DNA repair and cell cycle control. SNPs 
in these genes may lead to defective function and so defective DNA repair and cell 
cycling, events necessary for carcinogenesis. Neither gene has been extensively 
studied for CRC association so they would make ideal candidate genes for such 
studies and are the subjects of this thesis. They are described in more detail below.
1.2.8 Summary
Thus it can be seen that SNPs are potentially a powerful genetic tool. They can be 
used in population genetics studies as markers of disease genes, association analysis 
of patients and controls, and loss-of-heterozygosity in tumours. In considering their 
relevance to the development of disease, the fact that they constitute the most 
frequent genetic variations and therefore potential impact on clinical phenotypes, 
leads to the hypothesis that the risks of common, complex diseases, including 
cancer, are influenced by SNPs in key susceptibility genes. Although individual 
SNPs are unlikely to cause disease it is possible that combinations of SNPs can 
modify the risk of developing diseases. Developing an understanding of the 
relationship between SNPs and disease risk would potentially allow screening for 
diseases as, by definition, SNPs are inherited. Knowledge of an individual’s SNP 
genotype could be used to make risk assessments of their potential clinical 
phenotype and disease susceptibility and therefore guide therapy.
1.3 P53R2.
1.3.1 Alternative names.
p53-inducible ribonucleotide reductase small subunit 2 homologue.
1.3.2 Symbol.
P53R2.
1.3.3 Genebank accession number.
AB036532
1.3.4 OMIM accession number.
604712
1.3.5 Locus and size.
P53R2 is a 6213 base gene located at chromosome 8q23.1. It contains a coding 
region from nucleotide position 245 to 1300.
1.3.6 Function.
p53R2 has been shown to be a direct target for the tumour suppressor gene TP53 
and contains a 351 amino acid protein containing a 20-nucleotide p53 binding site
at intron 1 (Tanaka et al., 2000). It has also been shown to be induced by p73, one 
of the TP53 gene family (Nakano et al., 2000). TP53 is known to have an important 
function in regulating cell cycle arrest or apoptosis in response to genotoxic stress 
and DNA damage thus preventing proliferation of damaged cells, an important step 
in carcinogenesis (Nakamura, 2004). P53 exerts its function via control of a large 
family of target genes involved in cell cycle arrest, apoptosis, DNA repair, 
inhibition of angiogenesis, oxidative stress and chemotaxis.
P53R2 has an 80% homology to human ribonucleotide reductase small subunit 
(RNR R2), a cytoplasmic protein involved in catalysis of ribonucleoside 
diphosphate to deoxyribonucleotide (dNTP) conversion in DNA synthesis (Guittet 
et al., 2001). RNR R2 is S phase specific and together with a 90 KDa subunit, R l, 
forms a ribonucleotide reductase complex (RNR) to provide deoxynucleotide 
precursors for DNA synthesis in the proliferating cell. R2 expression is cell-cycle 
specific and its synthesis and degradation control the activity of RNR (Yamaguchi 
et al., 2001). R2 is not involved in the supply of dNTPs for DNA repair in resting 
cells and cells in G l, instead p53 induced p53R2 expression due to various 
genotoxic stresses (including y-irradiation, UV-irradiation, the cytotoxic antibiotics, 
actinomycin-D and adriamycin) leads to the p53R2 protein accumulating in the 
nucleus (Nakano et al., 2000, Yamaguchi et al., 2001, Yoshida et al., 2006), here 
the p53R2 protein forms an active tetrameric RNR complex with Rl supplying 
dNTP precursors for DNA repair (Guittet et al., 2001, Xue et al., 2003, Nakamura,
2004).
It has been shown that p52R2 transcription and binding to Rl are impaired in p53 
mutant cell lines, however where the p53 -  p53R2 DNA repair mechanism is 
impaired R2 is able to take over the role of p53R2 and supply the necessary dNTPs 
(Zhou et al., 2003, Lin et al., 2004).
The role ofp53R2 in DNA repair has been studied in vivo demonstrating the pivotal 
role of the gene in maintaining dNTP levels in resting cells (Kimura et al., 2003).
1.3.7 P53R2 Single Nucleotide Polymorphisms (Table 1.15).
A C to A transversion at nucleotide position 88 in the 5’ untranslated region (UTR) 
has been identified by a PCR-SSCP (polymerase chain reaction -  single-strand 
conformation polymorphism) detection method in 52 individuals (Smeds et al.,
2001). The SNP was found to have a population frequency of 18%. The effect of 
the SNP on p53R2 function remains obscure.
Three SNPs in the p53R2 gene have been identified by expressed sequence tag 
database analysis and confirmed in a Caucasian population by allele specific 
polymerase chain reaction and polymerase chain reaction/restriction fragment 
length polymorphism methods (Ye and Parry, 2002a). The polymorphisms are 
represented by an A to C transversion at nucleotide position 2752, an A to G 
transition at nucleotide position 2759 and a G to C transversion at nucleotide 
position 4696. The rare alleles at these positions were found at frequencies of 6%, 
6% and 15% respectively. All three polymorphisms fall with in the 3’ UTR and 
their effects on p53R2 expression and function is not known.
Three SNPs have been identified in the first intron of p53R2 by cold SSCP analysis 
of 210 individuals (Deng et al., 2005); a C>G transversion at nucleotide position 
789 occurring at a frequency of 8%, a G>A transition at nucleotide position 928 
occurring at a frequency of 10% and a T>C transition at nucleotide position 933 
occurring at a frequency of 1%. The frequencies of these three SNPs were not found 
to be significantly different in 163 sporadic colorectal adenomas. The functional 
significance of the SNPs is unknown.
SNP Location Rare Allele frequency Reference
88 O A 5’ UTR 18% (Smeds et al., 2001)
2752 A>C 3’ UTR 6% (Ye and Parry, 2002a)
2759 A>G 3’ UTR 6% (Ye and Parry, 2002a)
G>C 4696 3’ UTR 15% (Ye and Parry, 2002a)
789 O G Intron 1 8% (Deng et al., 2005)
928 A>G Intron 1 10% (Deng et al., 2005)
933 T>C Intron 1 1% (Deng et al., 2005)
Table 1.15: p53R2 SNPs
1.3.8 Role in carcinogenesis.
It is well understood that DNA damage is pivotal in carcinogenesis and the 
accumulation of genetic defects leads to loss of cell regulation and uncontrolled 
proliferation (Gibbs, 2003). Therefore cells have a complex mechanism for DNA 
damage surveillance and repair. The TP53 tumour suppressor gene is central to this 
mechanism and acts in response to DNA damage from a wide variety of cellular 
stresses by activating various pathways that can lead to cell cycle arrest, DNA 
repair and apoptosis (Nakamura, 2004). TP53 mutations are the most common 
genetic defects found in human malignancies. P53R2 is one of the many genes 
induced by p53 and is involved in DNA repair. Should the p53 -  p53R2 DNA repair 
mechanism fail then it can be imagined that genetic mutations may arise. In vitro 
studies of the effects of organic acids on ulcerative colitis -  cancer derived cell lines 
have demonstrated that disruption of the p53 -  p53R2 DNA repair mechanism is 
likely to play an important role in carcinogenesis (Yoshida et al., 2006). In vivo 
studies of Rrm2b-null mice (Rrm2b encodes p53R2) have suggested that
impairment of p53R2 results in the accumulation of genetic alterations and increase 
in the rate of spontaneous mutations (Kimura et al., 2003).
Expression and mutation analyses of p53R2 in gastric cancer, squamous cell 
carcinoma of the oesophagus and urinary tract transitional cell carcinoma did not 
find any association between the gene and diseases (Byun et al., 2002, Smeds et al., 
2002, Hayashi et al., 2004). A mutation of p53R2 has been discovered in a single 
urinary tract transitional cell carcinoma (Hayashi et al., 2004) leading to a Glul36 
—> Asp amino acid substitution, but its significance is unclear.
P53R2 expression has been found to be increased in oral squamous cell carcinoma 
and to be significantly associated with tumour stage and grade (Yanamoto et al.,
2003). This finding prompted the authors to speculate that p53R2 expression may 
be associated with oral carcinogenesis and may be a predictive factor in tumour 
development and chemoradiotherapy response.
A case-control study comparing the frequencies of three p53R2 SNPs in 163 
individuals with colorectal adenomas and 210 controls found no significant 
differences between the two populations (Deng et al., 2005).
1.3.9 Role in cancer chemoradiotherapy.
Differences in the responses of cancers to chemoradiotherapy (CRT) may, in part, 
be due to the genetic makeup of the tumour cells. Lack of p53R2 expression has 
been found to be associated with a favourable response of oesophageal squamous 
cell carcinoma to CRT (Okumura et al., 2005). Such knowledge could lead to the 
ability to better select candidates for CRT based on tumour expression analysis. 
Similarly enhanced sensitivity to 5-fluoruracil (5-FU) has been demonstrated in 
p53R2 silenced cancer cell lines (Yanamoto et al., 2005). 5-FU is a 
chemotherapeutic agent used to treat a wide range of cancers. That silencing of
p53R2 leads to increased sensitivity to 5-FU supports targeting p53R2 for gene 
therapy in order to enhance adjuvant therapy of cancer.
The role of iron in the cell cycle and in neoplastic proliferation has lead to the 
possibility of using iron chelators as anti-tumour agents (Le and Richardson, 2002). 
Doxorubicin has been shown to be a more effective chemotherapy when combined 
with the iron chelator deferoxamine (Blatt and Huntley, 1989). Both R2 and p53R2 
proteins have been shown to bind Fe through highly conserved residues (Le and 
Richardson, 2002, Kauppi et al., 1996). The enzymatic activity of the RR molecule 
is related to the molecule’s iron centre and iron chelation has been shown to impair 
the activity of RR, with p53R2 being more susceptible to iron chelators than R2 (Le 
and Richardson, 2002, Blatt and Huntley, 1989, Shao et al., 2004). This knowledge 
could lead to the development of new chemotherapeutic agents based on iron 
chelation.
1.3.10 Summary.
P53R2 is a p53 inducible DNA repair gene that has a crucial role in supplying 
dNTPs for DNA repair. Several SNPs have been discovered but their functional 
effects remain obscure. There is little evidence that p53R2 has a significant role in 
carcinogenesis, however further studies are required to fully elucidate p53R2 
function and role in carcinogenesis.
1.4 REPRIMO.
1.4.1 Symbol.
RPRM.
1.4.2 Genebank accession number.
AB043585
1.4.3 OMIM accession number.
1.4.4 Locus and size.
Reprimo is a 1510 base gene located at chromosome 2q23.3. The coding sequence 
is located between bases 244 to 573.
1.4.5 Function.
Reprimo acts down stream of the tumour suppressor gene p53 and is involved in 
cell cycle arrest at the G2 stage of the cell cycle in response to X-irradiation (Suzuki 
et al., 2006, Wong et al., 2005). Reprimo expression produces a glycosylated 
cytoplasmic protein and G2/M arrest of the cell cycle by inhibition of Cdc2 activity 
and nuclear translocation of cyclin B l. Arrest of damaged cells at G2 allows for 
DNA repair or apoptosis and thus protection from accumulation of mutations and
tumorigenesis. Reprimo dysfunction may lead to loss of cell cycle regulation and 
therefore contribute to tumorigenesis.
1.4.6 Reprimo Single Nucleotide Polymorphisms.
Two SNPs of the Reprimo gene have been identified using the human expressed 
sequence tags (ESTs) database (Ye and Parry, 2002b). The polymorphisms, a G to 
C transversion at nucleotide position 824 and a C to G transversion at position 839, 
were confirmed by allele specific polymerase chain reaction in a healthy Caucasian 
population. The allele frequencies of G and C alleles at position 824 were found to 
be 38.4% and 61.6% respectively and the frequencies of G and C alleles at position 
839 to be 3.7% and 96.3%. Both polymorphisms fall within the 3’ untranslated 
region of the gene.
There are no published Reprimo SNP -  cancer association studies to date.
1.4.7 Role in carcinogenesis.
Allelic imbalance of the Reprimo chromosomal locus, 2q23, is associated with 
human cancers, including lung, colon and breast, suggesting a tumour suppressor 
role (Zhang et al., 2002).
Lowered expression of Reprimo has been observed in mice with p53 germ line 
mutations exposed to the colon carcinogen 1,2-Dimthylhydrazine (DMH) 
(Takahashi et al., 2005). Exposure of these mice to DMH led to an increased 
incidence of uterine sarcomas, colon carcinomas, lung adenomas and hepatomas. 
Lowered Reprimo expression was presumed to lead to increased cell proliferation. 
Reprimo has been found to be aberrantly methylated in a number of cancers (Suzuki 
et al., 2005, Komazawa et al., 2004, Sato et al., 2003, Zhang et al., 2002, Taylor and
Stark, 2001, Ohki et al., 2000). Aberrant methylation of proto-oncogenes and 
tumour suppressor genes is an epigenetic event frequently observed in 
carcinogenesis. The effects of promoter region methylation on DNA binding and 
altered chromatin structure down regulate transcriptional activity leading to loss of 
gene function. Aberrant methylation of Reprimo has also been shown to be 
independent of p53 status supporting the hypothesis that Reprimo has a tumour 
suppressor gene function.
Reprimo has been shown to be up regulated by S100A2, one of the S I00 protein 
family thought to have a role in cancer progression (Matsubara et al., 2005).
1.4.8 Summary.
Reprimo is a p53 dependent gene involved in cell cycle regulation. Its chromosomal 
locus is recognised as being associated with human cancers. It is a putative tumour 
suppressor gene whose dysfunction due to altered regulation or aberrant 
methylation may be involved in carcinogenesis. Although SNPs have been 
discovered their effect on gene function or association with disease has not been 
studied.
1.5 DIVERTICULAR DISEASE.
1.5.1 Introduction.
Diverticular disease is an acquired condition of the colon caused by mucosal and 
sub mucosal herniations through the circular muscle layer (Mimura et al., 2002, Jun 
and Stollman, 2002). It is very common and represents an important disease in 
terms of health care costs in the Western world (Petruzziello et al., 2006). The 
disease covers a clinical spectrum from asymptomatic disease to uncomplicated 
symptomatic disease manifest by chronic abdominal pain and to complicated 
disease manifest by acute inflammation (diverticulitis), abscess formation, 
fistulation or stricture formation and bowel obstruction, and haemorrhage (Stollman 
and Raskin, 2004). At the severe end of this clinical spectrum diverticular disease is 
potentially fatal.
1.5.2 Prevalence.
The true prevalence of diverticular disease is difficult to establish as in most cases it 
is asymptomatic. However prevalence increases with age with rates of 5-10% under 
the age of 40, 30% over the age of 50, 50% over the age of 70 and 66% over the 
age of 80 in the Western world being generally accepted (Stollman and Raskin, 
2004, Delvaux, 2003, Jun and Stollman, 2002). The prevalence of diverticular 
disease appears to be increasing, this may be due to an increasingly elderly 
population, increasing bowel investigation due or due to a true prevalence rise 
(Delvaux, 2003, Jun and Stollman, 2002).
Bleeding and infective complications occur in around 5-15% and 15-20% of cases 
respectively (Jun and Stollman, 2002, Delvaux, 2003).
Diverticular disease occurs with equal frequency in both men and women, however 
more men under the age of 65 and more women over the age of 65 are admitted to 
hospital with diverticulitis (Jun and Stollman, 2002).
1.5.3 Geography.
Diverticular disease has been termed a ‘disease of Western civilisation’ due to the 
wide variation in geographical incidence. The prevalence of diverticular disease is 
highest in the industrialised nations (USA, Europe and Australia) and lowest in 
developing nations (rural Africa and Asia) (Kang et al., 2004, Stollman and Raskin, 
2004, Nakaji et al., 2002). Ethnic differences also exist within countries, for 
example a lower prevalence of diverticular disease in Indian-subcontinent Asians 
as compared with other ethnic groups living in Britain has been shown from a study 
of colonoscopy reports (Kang et al., 2004). The prevalence of diverticular disease 
within ethnic groups has been shown to rise as they are Westernized, demonstrated 
by the increase in prevalence from 3.8% to 12% and 0.7% to 5.4% in Shepardic 
Jews and Arabs, respectively, in Israel over ten years (Jun and Stollman, 2002). 
These findings suggest both environmental and genetic effects on the aetiology of 
diverticular disease.
The site of diverticula formation in the colon also has geographic variation with the 
left side of the colon being affected in Western populations and the right side in 
Asian and Oriental populations (Jun and Stollman, 2002, Nakaji et al., 2002, 
Simpson et al., 2002, Kang et al., 2004). Although the prevalence of diverticular 
disease may increase with Westernisation the anatomical site preponderance 
persists (Jun and Stollman, 2002) again suggesting a genetic component to the 
disease.
1.5.4 Aetiology.
Diverticular disease is an acquired disease of the colon and is thought to arise as a 
result of a prolonged low fibre diet interacting with changes in the bowel wall to 
cause increased pressure within the lumen of the bowel (Mimura et ah, 2002). This 
increased pressure causes herniations of the mucosal through the muscle wall at the 
points where blood vessels penetrate.
The role of fibre is well established in the development of diverticular disease. 
Vegetarians have been shown to have a lower incidence of diverticular disease than 
their carnivorous counterparts (Gear et al., 1979). It is thought that a diet low in 
fibre leads to a lower amount of stool within the colon (fibre is not absorbed and 
therefore serves to provide bulk to the stool). With fewer residues within the bowel 
as the muscles contract a higher intraluminal pressure is generated (Mimura et al., 
2002, Stollman and Raskin, 2004). This effect is compounded by stiffening of the 
bowel wall due to changes in the extracellular matrix. Electron microscopic studies 
of colonic walls have demonstrated elastosis (Whiteway and Morson, 1985) and 
structural and compositional changes in collagen have been demonstrated (Wess et 
al., 1995, Wess et al., 1996). However the relationship between the bowel wall 
changes and pathogenesis of diverticular disease remains unclear. One theory put 
forward involves altered activity of metalloproteinases, enzymes involved in the 
degradation of extracellular matrix components including elastin and collagen, 
leading to altered colonic wall structure (Simpson et al., 2003).
1.5.5 Genetic aspects of Diverticular Disease.
Diverticular disease is not generally considered to be a genetic disease, however 
there has been little research into its molecular pathology or genetic epidemiology,
and is generally held to be an environmental disease. Certain aspects of diverticular 
disease suggest at least a contribution from molecular mechanisms to its 
pathogenesis.
The ethnic differences in both the frequency of diverticular disease and the 
predilection for affecting the right colon in Eastern races may reflect a genetic 
influence on the aetiology of the disease (Kang et al., 2004, Simpson et al., 2002, 
Mimura et al., 2002, Nakaji et al., 2002). Although it has been suggested the 
difference in site predilection may be due to morphological differences in the colon 
between races (Nakaji et al., 2002).
There are also associations of diverticular disease with genetic connective tissue 
disorders. Marfan’s, William’s and Ehler’s-Danlos syndromes are diseases manifest 
by disorders of connective tissue. Marfan’s syndrome is due to a mutation in the 
fibrillin-1 gene, located on chromosome 15q21.1, and results in a number of 
abnormalities of collagen and elastin (Gray and Davies, 1996). The Ehler’s-Danlos 
syndromes are a group of inherited connective tissue disorders due to a defect in the 
type III collagen gene (2q31) (Yeowell and Pinnell, 1993). In type IV Ehler’s- 
Danlos, the most severe type, the bowel is affected. William’s syndrome is, again, a 
genetic connective tissue disease due to a deletion in the elastin gene, located at 
7ql 1.2. All three of these syndromes have been reported associated with premature 
diverticular disease (Beighton et al., 1998, Eliashar et al., 1998, Deshpande et al.,
2005). This would suggest that genetic factors can be responsible for the 
development of diverticular disease and leads to the supposition that acquired 
defects in genes involved in the extra-cellular matrix may be important in its 
development. Changes in type III collagen and reduced matrix metalloproteinase 1 
expression have been demonstrated in diverticular disease further supporting 
molecular pathological mechanisms in its development (Stumpf et al., 2001).
Further work is clearly needed in this area in order to unravel the complex nature of 
this common disease.
1.5.6 Diverticular disease and Colorectal Cancer.
Both diverticular disease and colorectal cancer share similar aetiological and 
symptomological features. Both are diseases of old age, of the developed world and 
are associated with a diet poor in vegetables. Both diseases present with altered 
bowel habit and rectal bleeding and can cause bowel obstruction and perforation. 
However whether there is a causal relationship between the two diseases, and 
especially whether diverticular disease can increase the risk of developing 
colorectal cancer remains controversial. It is well established that the inflammatory 
bowel diseases Crohn’s colitis and ulcerative colitis increase the risk of developing 
colorectal cancer and this stimulates the debate as to whether diverticular disease 
can cause colorectal cancer. However the evidence base is lacking. Some studies 
have shown that colorectal cancer is relatively common amongst patients with 
diverticular disease (Stefansson et al., 1995) and that there is an increased risk of 
left sided colon cancer (Stefansson et al., 1993). Other studies have shown an 
increased incidence of adenomas (precursors of cancer) in diverticular disease but 
that this does not necessarily indicate a causal association (Morini et al., 1988, 
Morini et al., 2002). Other studies still have shown that there is no significant 
association between the two diseases and that they represent heterogeneous groups 
(McCallum et al., 1987, Krones et al., 2006) or indeed that there is a lower 
incidence of colorectal cancer in patients with diverticular disease (Loffeld and 
Putten, 2001). The generally accepted view is that being diagnosed with diverticular 
disease does not increase an individual’s risk of developing colorectal cancer,
however any individual who presents with symptoms that suggest diverticular 
disease must be assumed to have colorectal cancer until proven otherwise.
1.5.7 Diverticular disease as a control disease in genetic studies of colorectal 
cancer.
People diagnosed with diverticular disease provide a reasonable and practical 
control group for colorectal cancer genetic studies. Both diseases have similar 
environmental and geographical aetiologies and affect a similar age group but there 
is not thought to be a causal relationship between the two diseases. Therefore 
diverticular disease provides well-matched controls for colorectal cancer studies. 
Diverticular disease is also a common disease and so potential control subjects are 
plentiful.
People who have been diagnosed as having diverticular disease will have had 
investigations that would detect colorectal cancer and so it can be ensured that 
individuals do not have colorectal cancer when used as control subjects.
1.5.8 Summary.
Diverticular disease is a common disease affecting the colon. It is a disease of 
advancing age and of the developed world. Lack of dietary fibre is an important 
aetiological risk factor. Although it is not known to be a genetic disease, ethnic 
differences in disease prevalence and pattern and its association with genetic 
connective tissue diseases suggest a likely underlying molecular pathology. 
Diverticular disease is not generally accepted to be causally related to colorectal 
cancer but does share demographic and aetiological factors and therefore provides a 
control disease for genetic studies of colorectal cancer.
Chapter 2
MATERIALS AND METHODS
2.1 INTRODUCTION
The following chapter gives the details of the methods followed in order to test the 
Reprimo G>C 824 and p53R2 C>G 4696 SNPs for association with CRC. The first 
step was to establish the frequencies of the SNPs in the study populations by 
genotyping each individual in the populations. DNA was extracted from buccal 
cells and analysed using polymerase chain reaction techniques to determine 
individual’s genotype. The population genotype frequency data was then analysed 
using an on-line statistical calculator specifically designed for SNP disease 
association studies.
2.2 METHOD DESIGN
A case-control study was used to test for genetic association between the Reprimo 
G>C 824 and p53R2 C>G 4696 SNPs.
2.3 ETHICAL CONSIDERATIONS
The ethical principles governing research as laid down by the General Medical 
Council (Council) were followed in designing and conducting the work presented in 
this thesis.
The Iechyd Morgannwg Health authority local research ethics committee granted 
approval for the research (reference: 2002.033).
Each participant was given an information sheet outlining the purpose of the 
research and informed consent was obtained from individuals within the study 
populations prior to obtaining biopsy samples (see appendices A and B). 
Confidentiality was guaranteed by removing identification from extracted DNA so 
that it was not possible to match a given genotype to an individual.
2.4 POPULATION SELECTION
Three populations were studied:
2.4.1 Study population.
A Colorectal cancer population derived from patients treated by the Department of 
Colorectal Surgery, Singleton Hospital, Swansea NHS Trust, Wales. Only patients 
who had had a histologically proven diagnosis of colorectal cancer were included in 
the study. Patients with coexistent inflammatory bowel disease (ulcerative colitis, 
Crohn’s disease etc.) or autosomal dominantly inherited CRC (FAP or HNPCC) 
were excluded. Patients with a family history of CRC were included.
2.4.2 Unmatched control population
A random population derived from students and staff of the Centre for Genetics and 
Toxicology, University of Wales Swansea. All students and staff who volunteered 
were included in the study. There were no exclusion criteria.
2.4.3 Matched control population.
A diverticular disease population derived from patients treated by the Department 
of Colorectal Surgery, Singleton Hospital, Swansea NHS Trust, Wales. Only
individuals with diverticular disease proven by radiological, endoscopic or 
histological means were included. Patients with coexistent inflammatory or 
malignant colorectal disease were excluded.
2.5 MATCHING CRITERIA.
2.5.1 Ethnic group.
Both the CRC and DD populations were derived from the same geographical area 
of South West Wales -  an area of relative ethnic homogeneity, with 98% of the 
population being Caucasian (www.statistics.gov.uk). The student population was 
taken from a more diverse ethnic mix.
2.5.2 Age.
Both CRC and DD are age related disorders becoming increasingly common with 
advancing age.
2.5.3 Environmental factors.
The matched CRC and DD populations were assumed to have similar 
environmental backgrounds on the basis of their similar geographical locations, 
ethnicity and ages. The unmatched student population was more diverse and so may 
have been exposed to different environmental factors.
2.6 METHODS TO OBTAIN DNA.
2.6.1 Sample Collection.
DNA samples were collected by buccal scraping biopsy using cytology brushes 
(Cytosoft Cytology Brush, Medical Packaging Corporation, Panorama City, CA 
91402, USA). The brush was rubbed over the buccal mucosa of participants, 
replaced in its packaging, identified with a patient label to allow data retrieval and 
the population from which the individual came from indicated on the packaging. 
The sample was then stored at -20°C until the DNA was extracted. Samples could 
be stored frozen indefinitely.
2.6.2 DNA Isolation Technique.
DNA isolation from collected buccal cell biopsies was performed using the 
Puregene™ DNA Purification System (Gentra Systems, Minnesota, USA). The 
system comprises the following five steps:
2.6.2.1 Cell Lysis.
Each biopsy brush was washed in 300pi of cell lysis solution (supplied in kit) and 
1.5pi proteinase K solution (20mg/ml) added. After thorough mixing the lysate was 
incubated at 55°C for 1-3 hours.
2.6.2.2 RNase Treatment.
1.5 pi RNase A solution was added to each lysate then thoroughly mixed and 
incubated at 37°C for 30 minutes.
2.6.2.3 Protein Precipitation.
The samples were cooled to room temperature and lOOpl of protein precipitation 
solution (supplied in kit) was added to each sample and thoroughly mixed by 
vortexing. The samples were then cooled in an ice bath for five minutes and then 
centrifuged at 13000rpm for 15 minutes at 4°C to form the precipitated protein into 
a pellet, visible at the bottom of the tube. If no pellet was visible, the sample was re- 
vortexed and centrifuged.
2.6.2.4 DNA Precipitation.
The supernatant containing the DNA was separated from the precipitated protein 
pellet, mixed with 300jil of 100% isopropanol and 0.5pl of glycogen solution 
(20mg/ml) and incubated at room temperature for five minutes. This solution was 
then centrifuged at 13000rpm for ten minutes at 4°C. (The DNA was visualized at 
the bottom of the tube as a small white pellet if the yield was large enough). The 
supernatant was removed and 300pl of 70% ethanol was added to wash the DNA. 
This solution was then centrifuged at 13000 rpm for five minutes at 4°C. The 
ethanol was carefully removed and the tube containing the DNA allowed to dry.
2.6.2.5 DNA Hydration.
The DNA was rehydrated by adding 20pl of purified water and incubating at 65°C 
for one hour or overnight at room temperature. The DNA samples were then stored 
at -20°C.
2.6.3 DNA Concentration Analysis and Standardisation.
As the yield of DNA from each biopsy varied it was necessary to establish the 
concentration of each isolated solution so that the concentrations could be 
standardized (30ng pi'1) for PCR and PCR/RFLP.
Each sample was thawed and vortexed to redisperse the DNA. 4pl of each sample 
was mixed with 96pl of purified water and the DNA concentration analysed in a 
spectrophotometer.
Samples with a concentration greater than 30ng pi'1 were diluted. The volume to be 
added (V) was calculated by the formula V = (Y x 16) -  16 where Y = 
(concentration of DNA/ 30) ng pi'1.
2.7 METHODS TO DETECT P53R2 O G  4696 AND REPRIMO G>C 824 
SINGLE NUCLEOTIDE POLYMORPHISMS.
NB: The p53R2 4696 SNP was described by Ye and Parry as a G>C 
transversion, with the G allele being rare (frequency 15%), as the G SNP 
appears in Genebank. However for this study the SNP is referred to as a C>G 
transversion as this nomenclature more accurately describes the SNP.
2.7.1 Reprimo G>C 824 - Allele specific polymerase chain reaction (PCR).
Allele specific PCR was used to detect a G to C transition at nucleotide position 824 
in the Reprimo gene using one downstream primer (REP-3) and two upstream 
primers (REP-1 and REP-2), differing in the terminal base. Primer sequences are 
those used by Ye and Parry and shown below (Table 2.1). Primers were obtained 
from MWG Biotech (Ebersberg, Germany). Each sample was tested in parallel 
reactions, with the same downstream primer and one of the upstream primers. The 
reaction mixture used for the PCR is given below. Amplification only took place if 
the tube contained an exact matching upstream primer, i.e. in both tubes for 
heterozygotes or in a single tube for homozygotes. The reactions were performed in 
a PTC-225 Peltier Thermal Cycler (MJ Research,Waltham, MA, USA). Conditions 
for the reactions are shown below. Each reaction also included negative controls, 
where no DNA was included in the reaction mix, in order to detect any 
contamination and positive controls using standard DNA control(l:10 dilution of 
Promega Human Genomic DNA, 185pl/ml) of known genotype, in order to check 
reaction was successful. PCR products were visualized on a 2.5% agarose gel with 
ethidium bromide staining (2g agarose melted in 100ml TrisBorateEDTA with lOpl 
ethidium bromide added).
2.7.1.1 Primers used to detect Reprimo G>C 824.
Reprimo G>C 824 (allele specific)
REP-1
5 - AG AGGGCG ATT AGGGCGC AG-3'
(Upstream)
REP-2 5 - AG AGGGCG ATT AGGGCGC AC-3'
(Upstream)
REP-3
5' - AGG AG A AG AGTGGG AGCGC-3'
(Downstream)
Table 2.1: Primers used to identify Reprimo G>C 824.
2.7.1.2 Reaction Mix for PCR.
1.5 mM MgCL
10 mM Tris-HCl Buffer, pH 8.8 
100 \iM each dNTP 
100 pmols Upstream Primer 
100 pmols Downstream Primer
2.5 U Taq DNA polymerase
2 \i\ template DNA solution (30ng/ pi).
In a total volume of 50pl.
2.7.1.3 Reaction Conditions.
5-minute denaturation at 94°C.
32 cycles at 94°C for 45 seconds, 62°C for 30 seconds, 72°C for 45 seconds. 
5-minute final extension at 72°C.
2.7.2 p53R2 C>G 4696 -  Polymerase chain reaction / restriction fragment 
length polymorphism (PCR/RFLP).
The polymerase chain reaction/restriction fragment length polymorphism method 
was used to detect a C to G transition at nucleotide position 4696 of the p53R2 
gene. This transversion creates a recognition site for the Hindlll restriction enzyme. 
A fragment containing the polymorphism was isolated and amplified by PCR using 
primers R2-6 and R2-7 (Table 2.2) using the same reaction mix as shown 
previously. lOpl PCR product was digested at 37°C in a mixture containing 2pi 
Hindlll restriction enzyme, 6pi purified water and 2pl buffer to give a total volume 
of 20 pi. The digested fragments were visualized on 2.5% agarose gel.
2.7.2.1 Primers used to detectp53R2 C>G 4696.
P53R2 C>G 4696 (PCR/RFLP)
R2-6 5 '-AGATGGAAGGCTGGGAGAAT-3'
R2-7 5 '-TTCTGTACATGCAGGCTTGG-3'
Table 2.2.: Primers used to identify p53R2 C>G 4696.
2.7.2.2 Reaction conditions.
5 minute denaturation at 94°C.
32 cycles of 94°C for 10 seconds, 57°C for 20 seconds and 72°C for 45 seconds. 
Final extension at 72°C for 5 minutes.
2.8 VALIDATION OF GENOTYPING TECHNIQUES.
To ensure the genotyping was accurate and to exclude genotyping errors 
confounding interpretation of results measures were taken to verify the fidelity of 
the techniques used.
2.8.1 Repeat genotyping.
As the most likely genotyping error in allele specific PCR results is false positive 
heterozygotes all Reprimo G>C 824 heterozygotes were checked by repeating the 
PCR reaction and gel electrophoresis.
2.8.2 Independent sequencing.
A total of nine randomly selected PCR products of hetero- and homozygotes of both 
Reprimo G>C 824 and p53R2 C>G 4696 from all three populations were purified 
using the Qiagen QIAquick® PCR Purification system (Hilden, Germany) and sent 
to MWG Biotech for sequencing in order to verify fidelity of methods to identify 
SNPs.
Sequencing was only performed with down stream primers therefore chromograms 
received from MWG showed complimentary and reversed sequences.
2.9 STATISTICAL ANALYSIS.
2.9.1 Population demographic data.
Gender distribution in the study populations was compared using a %2 test. Age 
distribution in the CRC and DD populations was compared using a t-test for means.
2.9.2 Population genotype and allele frequency analysis.
In order to test the SNPs for association with CRC they were tested for Hardy- 
Weinberg equilibrium and genotypic and allelic disease association on-line using 
the Finetti programme (http://ihg.gsf.de/cgi-bin/hw/hwal.pl) accessed via the 
Genestat Statistical Genetics web site (http://www.genestat.org). The programme 
generates expected genotype frequencies, allele frequencies and inbreeding 
coefficient (F) from observed genotype frequencies. Deviation from Hardy- 
Weinberg equilibrium is tested by Pearson’s goodness-of-fit, Log likelihood ratio 
and exact chi-square tests (with 1 degree of freedom). Tests for association are 
performed using chi square and odds ratio for allele-, heterozygote- and 
homozygote- frequency differences, allele positivity and Armitage’s trend test. The 
tests were carried out twice for each SNP using both control populations. P values 
of less than 0.05 were significant.
2.9.2.1 Hardy -  Weinberg Equilibrium (HWE).
The Hardy -  Weinberg law states that allele frequencies remain in equilibrium in
9  9large, randomly mating populations and is expressed by the formula p +2pq+q =1 
where p and q are the frequencies of the alleles A and a. From this formula the
allele and expected genotype frequencies can be derived from the observed 
genotype frequencies according to the following formulae; where the observed 
frequencies of the genotypes AA, Aa and aa are x, y and z in a population size of n 
then the frequencies of the alleles A and a are (2x+y)/n and (2z+y)/n respectively. 
The expected genotype frequencies in the population are thus (A )n, (2Aa)n and 
(a2)n.
2.9.2.1.1 Deviation from HWE.
Deviation from HWE is tested using Pearson’s goodness-of-fit, log likelihood ratio 
and exact % tests to compare the observed and expected allele frequencies, as
calculated using the Hardy-Weinberg equation. Three tests are used as the goodness
2 2of fit test (x = L (O -E) /E) may be inaccurate when the expected frequencies are 
low or the sample sizes are small. In these cases, respectively, the log likelihood 
ratio and exact tests are more appropriate.
2.9.2.2 Inbreeding coefficient.
The inbreeding coefficient is defined as the probability that two alleles in an 
individual are identical by descent (autozygous) and is a measure of genotypic 
frequency deviation from panmictic frequencies in terms of heterozygous 
deficiency or excess. Calculated by the formula F= (H 0bs/Hexp) where H 0bS and H exp 
are the observed and expected heterozygosity. Negative and positive values of F 
indicate heterozygous excess (outbreeding) and deficiency (inbreeding) 
respectively. Although deviation from H W E  can be due to causes other than
inbreeding, the inbreeding coefficient gives a good indication of the degree of HWE 
deviation.
2.9.3 Tests for disease -  SNP association.
Association between the study SNPs and CRC were tested using odds-ratio and 
Pearson’s goodness-of-fit % tests. A range of tests are performed; allele frequency 
difference, heterozygous, homozygous, allele positivity and Armitage’s trend test in 
order to account for different models of penetrance i.e. dominant, recessive, 
additive, multiplicative or no specific model. Each genetic model generates a 
different contingency table to which the x test is applied. The tests are performed 
with respect to each SNP allele, as it is not known which allele potentially confers 
disease risk.
For an SNP with alleles A and B the full genotype contingency table will be;
AA AB BB
Cases a b c
Controls d e f
where a, b, c, d, e and f  are observed genotype counts.
The x statistic tests for differences between the observed and expected genotype 
numbers in each cell of the table. If the observed (O) AA genotype number in cases 
is a, the expected (E) number of AA cases is «AA«cas(/N i.e. 
(a+b)x(a+b+c)/(a+b+c+d+e+f). The x2 statistic is thus x2 = 2 (O -E )2/E.
The odds ratio (OR) indicates the increase in disease risk for carriers as compared 
with non-carriers and is calculated as the ratio of candidate allele carriers to non­
carriers in the disease population compared with that in the control population, i.e.: 
OR = [(b+c)d]/[a(e+f)] for the above contingency table.
2.9.3.1 Allele frequency difference test.
This test assumes a multiplicative penetrance model where the genotype AB 
increases risk by r and the genotype BB increases risk by r . The contingency table 
for this model is:
A B
Cases 2a+b b+2c
Controls 2d+e e+2f
2.9.3.2 Heterozygous and homozygous tests.
These tests assume no specified relationship with the genotypes. The contingency 
tables generated are:
AB AA
Cases b a
Controls e d
for the heterozygous test with respect to the A allele,
AA BB
Cases a c
Controls d f
for the homozygous test.
2.9.3.3 Allele positivity test.
This test assumes a dominant or recessive penetrance model. The contingency 
tables generated are:
BB AA+AB
Cases c a+b
Controls f d+e
for a dominant model with respect to A (single copy of A increases risk) or
AB+BB AA
Cases b+c a
Controls e+f d
for a recessive model with respect to A (two copies of A increases risk).
2.9.3.4 Armitage’s trend test
Assumes an additive penetrance model where the genotype AB increases risk by r 
and the genotype BB increases risk by 2r with respect to risk allele B. The 
contingency table tested will be:
AA AB BB
Cases a b c
Controls d e f
2.10 SUMMARY.
Ethical approval was granted for the study. Three populations (healthy, diverticular 
disease and CRC) were genotyped with respect to the Reprimo G>C 824 and p53R2 
C>G 4696 SNPs using allele specific PCR and PCR/RFLP techniques. Repeat 
genotyping and independent sequencing of PCR products tested the validity of the 
genotyping technique. The populations were tested for Hardy-Weinberg equilibrium 
and CRC association with respect of the candidate SNPs and differing modes of 
penetrance.
Chapter 3
PRELIMINARY WORK AND OPTIMISATION OF 
GENOTYPING TECHNIQUES
3.1 INTRODUCTION.
This chapter will describe how the methodology described in the “materials and 
methods” chapter was developed. It will describe how the research method was 
designed in order to investigate the hypothesis that Reprimo and p53R2 SNPs are 
associated with CRC. The original intention was to investigate three previously 
described p53R2 SNPs (at nucleotide positions 2752, 2759 and 4696) and two 
Reprimo SNPs (at nucleotide positions 824 and 839) (Ye and Parry, 2002b, Ye and 
Parry, 2002a) however only two SNPs (p53R2 C>G 4696 and Reprimo G>C 824) 
were studied for disease association with CRC. This was because either the SNPs 
were not detected in the study populations using the methods previously described, 
or the published methods failed or despite optimisation experiments it was not 
possible to detect the SNPs. The problems encountered and how they were 
overcome is detailed below.
It s important to emphasise that the work described below took up to around a third 
of the total time spent in the laboratory during this study.
3.2 POPULATION SELECTION.
Three populations were studied in this work; a young healthy population, a 
population of patients known to have CRC and a population of patients known to 
have diverticular disease. The young population had had tissue samples pre­
collected prior to the start of the study and the DNA extracted was used to optimise
the conditions and techniques for the study SNP detection. It was also used to 
establish the frequency of the study SNPs in the general population. However it was 
realised that in case-control study a better matched population was required in order 
to eliminate any bias or confounding factors in the results that may be due to age. 
Therefore a population with diverticular disease was chosen as it is a common 
disease affecting a similar age group as CRC, but the two diseases have not been 
shown to be causally related.
3.3 POPULATION SIZE.
The size of the populations used was based on sizes of populations used in similar 
studies published prior to or at the time of the beginning of the study (2002) (Jong 
et al., 2002, Houlston and Tomlinson, 2001). Many published SNP disease 
association studies had used sample sizes of around one hundred individuals or less 
and it was felt that population sizes of one hundred would be sufficiently powerful 
to answer the question posed and more importantly that it would be feasible to 
collect and analyse the DNA within the time limits of the research period.
3.4 PROBLEMS WITH VISUALISING PCR PRODUCTS.
In Ye and Parry’s papers all PCR and PCR/RFLP products were visualised on 2.5% 
agarose gels. It was felt that as the products were all around 250 base pairs (bp) in 
length, visualisation on acrylamide gels might be more appropriate. Therefore 
experiments to test this were performed using Promega human genomic DNA 
(Promega Corporation, Madison, WI 53711, USA), a standardised source of DNA, 
and samples collected from a population of students and laboratory staff (Control 
population 1). Allele specific PCR was used to detect an A>C transversion at
nucleotide position 2752 of the p 5 3 R 2  gene, using conditions published by Ye and 
Parry.
These experiments resulted in gels with multiple bands, the strongest band 
appearing at around 400bp, fainter bands at 600bp and 900bp and, importantly, no 
bands at 249bp. the length of the expected PCR product using these conditions 
(Figure 3.1).
control
F igure 3.1: Typical acrylamide gel appearance follow ing p53R 2  A>C 2752 allele specific PCR. The 
control lane contained no DNA in reaction to control for contamination (negative control) (bp = base
pairs).
Therefore it was decided to use 2.5% agarose gels and indeed expected band sizes 
were visualised.
3.5 PROBLEMS IDENTIFYING P53R2 SNPS.
3.5.1 SNP 1: A>C transversion at nucleotide position 2752.
Ye and Parry used an allele specific PCR technique to identify the p 5 3 R 2  A>C 
2752 SNP with the following conditions and primers:
Upstream primer (R2-1) 5'-GGATGAAGAAGTCTTAATACTGAA-3’
Upstream primer (R2-2) 5 ’-GGATGAAGAAGTCTTAATACTGAC-3’
Downstream primer (R2-3) 5'-AAGATCTCAAGTTTCTGACAGTG-3’
Table 3.1: Primers used to detect p53R2 A>C 2752
The reaction mix used was a 50ul solution containing 1.5mM MgCU, lOmM Tris- 
HCL, pH 8.8, lOOpM each dNTP, 10 pmol each primer, 2.5 U T a q  polymerase and 
0.5pg template DNA. Amplification conditions were; a 5-minute initial 
denaturation at 94° C, followed by 32 cycles of 94° C for 45s, 57° C for 30s, 72° C 
for 45s with a final extension at 72° C for 5 minutes.
These conditions were followed using Promega DNA and collected samples and the 
products visualised on 2.5% agarose gel.
Negative controls were included, where no DNA was included in the reaction mix, 
in order to detect any contamination that might confound results.
However this method invariably detected the rare A allele in all samples, an 
unexpected result given that Ye and Parry found the frequency of the rare A allele 
6% (Figure 3.2).
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Figure 3.2: Typical agarose gel for p53R2 A>C 2752 using Ye and Parry conditions. The rare 
A allele is detected in all sam ples. The two control lanes were negative controls and here 
indicate no contam ination took place.
Therefore a series of experiments was conducted with various different PCR 
conditions in order to optimise the conditions. These involved performing the PCR 
with a re-annealing temperature gradient from 55°C to 65°C (Figure 3.3), varying
the DNA concentration from 1:10 to 1:100 dilutions (Figure 3.4) and varying the 
number of reaction cycles from 30 to 35.
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Figure 3.3: Typical agarose gel for p53R2 A>C 2752 PCR re-annealling tem perature gradient 
experim ents. Re-annealling tem perature is shown across top of Figure.
Figure 3.4: Typical agarose gel fo r p53R2 A>C 2752 PCR DNA concentration gradient
experiments.
However none of these experiments yielded accurate results that would allow 
confident identification of the alleles. Time constraints forced these experiments to 
be abandoned to allow the project to progress.
3.5.2 SNP 2: A>G transition at nucleotide position 2759.
A PCR/RFLP technique was used by Ye and Parry to identify the p 5 3 R 2  A>G 2759 
polymorphism. The A>G transition eliminates a 7s/?509I restriction enzyme 
recognition site. The reaction mix was the same as for the A>C 2752 SNP. The 
primers used to detect the p 5 3 R 2  A>G 2759 SNP are shown in table 3.2. 
Amplification conditions were: a 5-minute initial denaturation at 94° C, followed by 
32 cycles of 94° C for 25s, 57° C for 30s, 72° C for 45s with a final extension at 72°
C for 5 minutes. The PCR product was then digested overnight with the T s p 5 0 9 \  
restriction enzyme at 65° C. The digested products were visualised on 2.5% agarose 
gel.
R2-4 5'-GATAGCCAATGGTGAGGGAA-3’
R2-5 5 ’ - AC AGTTTGTTGGG A ATGGG A-3 ’
Table 3.2: Primers used to detect p53R2 A>G 2759.
These conditions were used to successfully genotype the whole of control 
population 1. However the G allele was not identified in any sample (Figure 3.5). 
Therefore it was not possible to confirm the existence of the A>G transition at 
nucleotide position 2759 and this SNP was not studied further in either the CRC or 
diverticular disease populations.
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Figure 3.5: Typical agarose gel for p53R2 A>G 2759 PCR/RFLP. Each lane represents a single 
DNA sample. The single bands indicate that the PCR products have not cut with the restriction 
enzyme indicating that the G allele was not present in any sample. Samples are arbitrarily
numbered for sake of figure.
3.5.3 SNP 3: C>G transversion at nucleotide position 4696.
A PCR/RFLP technique was used by Ye and Parry to identify the p 5 3 R 2  C>G 4696 
polymorphism. The G>C transition eliminates a H i n d \ \ \  restriction enzyme 
recognition site. The reaction mix was the same as for the A>C 2752 SNP. 
Amplification conditions were: a 5-minute initial denaturation at 94° C, followed by 
32 cycles of 94° C for 10s, 57° C for 20s, 72° C for 45s with a final extension at 72° 
C for 5 minutes. The PCR product was then digested overnight with the H in d lU
restriction enzyme at 37° C. The digested products were visualised on 2.5% agarose 
gel.
R2-6 5’- AGATGGAAGGCTGGGAGAAT-3’
R2-7 5’- TTCTGTACATGCAGGCTTGG-3’
Table 3.3: Primers used to detectp53R2 C>G 4696.
This technique successfully identified the polymorphism and was used in the study 
presented in this thesis (see figure 4.2, page 93 for example of electrophoresis gel).
3.6 PROBLEMS IDENTIFYING REPRIMO SNPS.
3.6.1 SNP 1: G>C transversion at nucleotide position 824.
Ye and Parry used an allele specific PCR technique to identify the Reprimo C>G 
824 SNP with the following conditions and primers:
Upstream primer (REP-1) 5 ’ - AG AGGGCG ATT AGGGCGC AG-3 ’
Upstream primer (REP-2) 5’-AG AGGGCGATT AGGGCGC AC-3’
Downstream primer (REP-3) 5’-AGGAGAAGAGTGGGAGCGC-3’
Table 3.5: Primers used to detect Reprimo C>G 824
The reaction mix used was the same as for the p53R2 SNPs. Amplification 
conditions were; a 5-minute initial denaturation at 94° C, followed by 32 cycles of 
94° C for 45s, 60° C for 30s, 72° C for 45s with a final extension at 72° C for 5 
minutes. The products were visualised on 2.5% agarose gel.
These conditions were followed using Promega DNA and samples from the young, 
student population. However, although these methods yielded products of 
appropriate size (249 bp) multiple fainter bands were also visualised (Figure 3.6).
control control
Figure 3.6: Typical agarose gel for Reprimo G>C 824 allele specific PCR using Ye and Parry's
conditions.
Therefore performing the process with a re-annealing temperature gradient 
optimised the re-annealing temperature. This gave an optimum re-annealing 
temperature of 62°C (compared with 60°C) which reliably produced correctly sized 
products (see figure 4.1, page 92 for example of electrophoresis gel). The altered 
conditions were adopted for the subsequent work.
3.6.2 SNP 2: C>G transversion at nucleotide position 839.
Ye and Parry used an allele specific PCR technique to identify the R e p r im o  C>G 
839 SNP with the following conditions and primers:
Upstream primer (REP-6) 5’-GCGCAGAACTTTGGAAGCTGC-3’
Upstream primer (REP-7) 5’-GCGCAGAACTTTGGAAGCTGG-3’
Downstream primer (REP-3) 5 ,-AGGAGAAGAGTGGGAGCGC-3’
Table 3.6: Primers used to detect Reprimo C>G 839
The reaction mix and amplification conditions used were the same as for the p 5 3 R 2  
SNPs. These conditions were followed using Promega DNA and collected samples 
and the products visualised on 2.5% agarose gel. This method did not reliably yield 
the expected products. Optimisation experiments with re-annealing temperature 
gradients did not produce reliable conditions (Figures 3.7 and 3.8).
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Figure 3.7: Reprimo C>G 839 allele specific PCR re-annealling at 58°C. The control lanes are 
both negative controls. No distinct bands are seen indicating failure of the PCR to detect the
SNP.
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Figure 3.8: Reprimo C>G 839 allele specific PCR re-annealling at 59.5°C. Control lanes are 
negative controls. Lack of distinct bands indicates PCR failure.
Therefore, as the G polymorphism creates a recognition site for the R s a \  restriction 
enzyme, a PCR/RFLP technique was used to detect this polymorphism. The PCR 
products generated using the primers to identify the R e p r i m o  C>G 824 SNP 
contained the C>G 839 polymorphism site, therefore these primers were used in the 
PCR/RFLP technique to identify the C>G 839 polymorphism. The PCR products 
were then digested overnight at 37°C with the R s a \  restriction enzyme. However the 
rare G allele was not identified (Figure 3.9). Due to time constraints, further work to 
detect the R e p r i m o  839 C>G SNP was not carried out.
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Figure 3.9: Agarose gel dem onstrating Reprimo C>G 839 PCR/RFLP experim ent. The RFLP 
product lanes show that the PCR products did not cut with the Rsa I restriction enzyme 
indicating that the G allele was not present.
3.7 STATISTICAL METHODS.
The genotypic and allelic data obtained in this study is categorical. In order to 
examine the phenotypic-genotypic relationship (i.e. disease-association) y2 tests 
can be used to compare the observed with the expected genotype frequencies. 
The expected allele frequencies can be determined using the Hardy-Weinberg
7 7equation, p“+2pq+q"=l (where p and q are the allele frequencies). This was the 
approach taken early in the research. However as the research progressed 
literature searches revealed that this approach is too simplistic for SNP disease 
association studies as it does not take into account sample size, departures 
from HWE or the mode of penetrance, factors that can influence 
interpretation of results (Hattersley and McCarthy, 2005b, Hosking et al., 
2004b, Gordon et al., 2002b, Lewis, 2002b, Ohashi et al., 2001, Slager and 
Schaid, 2001a, Wittke-Thompson et al., 2005b). It also became apparent that 
statistical calculators are available on-line specifically designed for SNP studies 
that take into account these important factors. Therefore all the statistical tests 
for this study were performed using the Finetti program (accessed at 
http://ihg.gsf.de/cgi-bin/hw/hwal .p l). This program tests for HWE (using exact, 
goodness of fit and log likelihood y2tests), the inbreeding coefficient and tests 
for allelic and genotypic disease association. The tests are described in greater 
detail in Section 2.9 of the Methods chapter.
3.8 SUMMARY.
Three populations were used to avoid age related bias; diverticular disease was used 
as a suitable, easily obtainable matched control disease. Population sizes were 
similar to previously reported SNP association studies and feasible within the time 
period of the research.
Three of the five previously reported SNPs were not detected in preliminary 
experiments and so only the p53R2 C>G 4696 and Reprimo C>G 824 
polymorphisms were studied with respect to their association with CRC by a case- 
control method. Statistical analysis was performed using an on-line SNP disease- 
association calculator.
Chapter 4 
RESULTS
4.1 INTRODUCTION
The following chapter details the results obtained from the study methods as 
described in Chapter 2.
Tables are used to show results of statistical analysis where appropriate and results 
are given to two decimal places. P values less than 0.05 are taken as statistically 
significant and are shown in red.
4.2 POPULATION DATA
4.2.1 Colorectal cancer population
96 volunteers (32 female, 64 male, gender ratio 1:2).
Mean age 68 years (standard deviation = 9.9 years).
100% Caucasian.
4.2.2 Student population
107 volunteers (69 female, 38 male, gender ratio 1:0.6).
Mean age 19.3 years (standard deviation = 1.9 years).
92% Caucasian, 3% Middle Eastern, 2% Asian, 2% Oriental, 1% South 
American.
4.2.3 Diverticular disease population
52 volunteers (37 female, 15 male, 1:0.4).
Mean age 67.7 years (standard deviation 11.0 years).
100% Caucasian.
4.3 COMPARISON OF GENDER DISTRIBUTION IN MATCHED CRC 
AND DD POPULATIONS { f  TEST).
There was a significant difference in gender distribution between the CRC and 
diverticular disease populations (Table 4.1).
Gender CRC Population DD Population t P value
Male 62 15
Female 34 37
17.90 <0.01
Table 4.1: comparison of gender distribution in matched populations CRC and DD (x2 test).
4.4 COMPARISON OF MEAN AGES IN MATCHED CRC AND DD
POPULATIONS (t-TEST).
There were no significant differences in the mean ages of the CRC and diverticular 
disease populations (Table 4.2).
CRC
Population
DD
Population
Difference
t value 
(95% confidence 
interval)
P value
Population
size
96 52
Mean age 
(years)
68 67.7 0.3
0.17 
(-3.2 to 3.8)
0.87
Standard
deviation
9.9 11.0
Table 4.2: Comparison of mean ages in matched populations CRC and DD (t-test).
4.5 DNA COLLECTION
4.5.1 Acceptability.
The methods for canvassing volunteers and collecting tissue samples for DNA 
analysis were well accepted by patient volunteers, with only very small numbers 
refusing to take part in the study. Most volunteers were enthusiastic and often 
extremely interested in the study. No adverse events were encountered in 
performing buccal scrape biopsies.
4.5.2 Efficiency.
The methods for canvassing and collecting tissue samples for DNA analysis were 
very time consuming and labour intensive resulting in a smaller diverticular disease 
population than intended. Indeed, tissue sample collection was an important rate 
limiting step in this study. Ethical approval was only granted some three months
into the study, from when sample collection could begin. This left 21 months to 
collect samples. However in this time it was only possible to collect 96 CRC and 52 
diverticular disease samples, giving a collection rate of seven samples per month.
4.6 DNA ISOLATION.
4.6.1 DNA Yield.
The average DNA concentration obtained from the buccal scrapings was 2.94ng/ml 
(range 0.29 -  16.51ng/ml). This gave an average volume of DNA solution from 
each subject of 40.31 pi (range 16 -  220pl).
4.7 GENOTYPING
4.7.1 Error Rate.
4% of all samples were not successfully genotyped for both SNPs studied.
4.7.1.1 Reprimo G>C 824.
Student population -  6% (6/107) samples were not successfully genotyped. 
Diverticular disease population -  2% (1/52) samples were not successfully 
genotyped.
Colorectal cancer population -  2% (2/96) samples were not successfully genotyped.
4.7.1.2 P53R2 C>G 4696.
Student population -  4 %  (4/107) samples were not successfully genotyped. 
Diverticular disease population -  4 %  (2/52) samples were not successfully 
genotyped.
Colorectal cancer population -  3 %  (3/96) samples were not successfully genotyped.
4.8 ELECTROPHORESIS GELS
4.8.1 Reprimo G>C 824 (Allele specific PCR)
Two electrophoresis columns represent each individual’s genotype, one for each 
allele. Amplification only took place in one of the reactions if the individual was a 
homozygote or in both reactions if the individual was a heterozygote, visualised as 
a single or double band pattern on electrophoresis as shown below (Figure 4.1).
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Figure 4.1 Electrophoresis gel showing band patterns for Reprimo G>C 824 SNP genotypes. 
Each sam ple requires two reactions to detect each allele and is therefore represented in two 
lanes, a band being visualised at 249bp if the allele is present. The positive control (standard 
human DNA) genotype is GG, sam ple 1 GC and sam ple 2 CC. Samples are arbitrarily
numbered for sake of figure.
4.8.2 P53R2 C>G 4696(PCR/RFLP)
Each individual's genotype is represented in a single column. GG homozygotes 
have no H in d  III  digestion site and so PCR products do not cut yielding a single 228 
base pair band. Each allele of CC homozygotes contains the digestion site and so all 
PCR products are cut, yielding two bands of 149 and 78 base pairs. Heterozygous 
individuals show a mixture of these patterns, yielding three bands of 228, 149 and 
78 base pairs (Figure 4.2).
300bp
%
200bp
Negative Sample 1 Sample 2 Sample 3 
control
100bp N
Lane DNA
Ladder
Figure 4.2 Electrophoresis gel showing band pattern for P53R2 C>G 4696SNP genotypes. Each 
sample is represented in a single lane. The G allele is represented by a single 228bp band and, 
as the C allele creates the restriction site, presence of the C allele is shown by two bands at 
149bp and 78bp. Positive control was omitted from  this reaction. Samples are arbitrarily
numbered for sake of figure.
4.8.3 Multiple sample genotyping gel for Reprimo G>C 824 (Figure 4.3).
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Figure 4.3: Typical electrophoresis gel obtained from allele specific PCR Reprimo G>C 824 
SNP genotyping of multiple sam ples. Lanes 1 and 2 are contam ination (negative) control lanes. 
Lanes 3 and 4 are standard DNA (positive) control lanes, showing the standard DNA to be a 
GG hom ozygote. Sample 1 is a GC heterozygote and sam ples 2, 3 and 4 are CC homozygotes. 
Samples are arbitrarily num bered for sake of figure.
4.8.4 Multiple sample genotyping gel for p53R2 C>G 4696 (Figure 4.4).
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Figure 4.4: Typical electrophoresis gel obtained from PCR/RFLP P53R2 C>G 4696SNP  
genotyping of m ultiple sam ples. Triple band patterns shown in samples 4 and 7 and positive 
control (standard Promega human genomic DNA) represent GC heterozygotes. Double band 
pattern represents CC homozygotes. The GG hom ozygote is not shown, hut would be 
represented by a single band. Samples are arbitrarily numbered for sake of figure.
4.9 VERIFICATION OF GENOTYPING FIDELITY.
The results of genotyping initially showed an excess of R e p r i m o  G>C 824 
heterozygotes in the diverticular disease and CRC populations, raising the 
possibility of genotyping errors. Therefore all diverticular disease and CRC samples 
were re-genotyped for R e p r im o  G>C 824. 7 /145 (5%) genotyping errors were 
identified amongst the heterozygotes and one genotyping error amongst the 
homozygotes.
In order to verify that the genotyping techniques were identifying the correct allele 
by isolating the correct nucleotide sequence, three representative homozygous and 
heterozygous samples for both study SNP and from each of the three populations 
were sent for sequencing for both study SNPs at an independent laboratory. All 
samples sent for sequencing had genotypes as expected from the PCR or 
PCR/RFLP genotyping. Examples of chromograms demonstrating the nucleotide 
sequences containing the alleles under study are shown below (Figures 4.5 -  4.10).
4.9.1 Reprimo G>C 824 chromogranis.
SNPs are indicated by arrows.
4
T T A G G G C G C A  G A A C T  T T G G A
Figure 4.5: Chroniograni dem onstrating Reprimo G>C 824 G honiozygote (nucleotide 824
arrowed).
4
T T A G G G C G  C A G A A  C T T T G G A
C
Figure 4.6: Chroniograni dem onstrating Reprimo G>C 824 GC heterozygote (nucleotide 824
arrowed).
4
T T A G G G C G C  A C A A C T  T T G G A
Figure 4.7: Chroniograni dem onstrating Reprimo G>C 824 CC honiozygote (nucleotide 824
arrowed).
4.9.2 P53R2 C>G 4696 chromograms.
SNPs are indicated by arrows.
4
A C A T A G A A  A G G T T T A  T T A T G
Figure 4.8: Chromogram  dem onstrating p52R2 C>G 4696 GG honiozygote (nucleotide 4696 
arrowed).
4
A C A T A G  A A  A G G T T  T A T T A T G
C
Figure 4.9: Chroniograni dem onstrating p52R2 C>G 4696 GC heterozygote (nucleotide 4696
arrowed).
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A C A T A  G A  A A G C T T T A  T T A T G
Figure 4.10: Chromogram  dem onstrating p52R2 C>G 4696 CC hom ozygote (nucleotide 4696
arrowed).
4.9.3 GENOTYPE FREQUENCIES.
4.9.3.1 Reprimo G>C 824.
The observed and expected R e p r i m o  G>C 824 genotype frequencies are shown in 
Table 4.3.
DIVERTICULAR COLORECTAL
STUDENT
DISEASE CANCER
POPULATION
POPULATION POPULATION
Genotype Observed Expected Observed Expected Observed Expected
GG 28 (28%) 27 10(19%) 14 13(14%) 17
GC 48 (47%) 50 34 (67%) 25 55 (58%) 46
CC 25 (25%) 24 7(14%) 11 26 (28%) 30
Table 4.3: Genotype frequencies, Reprimo G>C 824.
4.9.3.2 P53R2 C>G 4696.
The observed and expected p53R2 C>G 4696 genotype frequencies are shown in 
Table 4.4.
STUDENT
POPULATION
DIVERTICULAR
DISEASE
POPULATION
COLORECTAL
CANCER
POPULATION
Genotype Observed Expected Observed Expected Observed Expected
GG 2 (2%) 1 1 (2%) 0 1 (1%) 1
GC 15(16%) 17 2 (4%) 4 12(13%) 13
CC 88 (82%) 87 46 (94%) 45 82 (86%) 82
Table 4.4: Genotype frequencies,p53R2 C>G 4696.
4.9.4 ALLELE FREQUENCIES.
4.9.4.1 Reprimo G>C 824.
In both the student and diverticular control populations the C allele was rarer than
the G allele, however in the CRC population the G allele was rarer (Table 4.5).
DIVERTICULAR COLORECTAL
STUDENT
DISEASE CANCER
POPULATION
POPULATION POPULATION
Allele Number Frequency Number Frequency Number Frequency
G 104 51 % 54 53% 81 43%
C 98 49% 48 47% 107 57%
Table 4.5: Allele frequencies, Reprimo G>C 824. 
4.9.4.2 P53R2 C>G4696.
In all three populations the G allele was the rare polymorphism (Table 4.6).
DIVERTICULAR
STUDENT
DISEASE
POPULATION
POPULATION
COLORECTAL
CANCER
POPULATION
Allele Number Frequency Number Frequency Number Frequency
G 19 9% 4 4% 14 7%
C 191 91% 94 96% 178 93%
Table 4.6: Allele frequencies, p53R2 C>G 4696.
4.10 STATISTICAL ANALYSIS.
4.10.1 TESTS FOR HWE.
4.10.1.1 Reprimo G >C 824.
Student Diverticular disease Colorectal cancer
population population population
Pearson’s goodness
P =0. 63
of fit x2 (df = 1).
P = 0.02 P = 0.06
Log likelihood ratio
P = 0.63
Z2 (d f= l) .
P = 0.02 P = 0.06
Exact test. P = 0.69 P = 0.03 P = 0.09
Table 4.7: HWE tests, Reprimo G>C 824.
4.10.1.2 P53R2 C>G 4696.
Student Diverticular disease Colorectal cancer
population population population
Pearson’s goodness 
of fit x2 (df = 1).
P = 0.18 P = 0.01 P = 0.47
Log likelihood ratio 
y2 (df = l).
P = 0.23 P<0.01 P = 0.51
Exact test.
P = 0.19 P = 0.06 P = 0.40
Table 4.8: HWE tests, p53R2 C>G 4696.
All three tests for deviation from HWE show that the Diverticular disease 
population deviates from HWE with respect to Reprimo G>C 824. Inspection of the 
observed and expected genotype frequencies reveals that there is an excess of GC 
heterozygotes in the Diverticular disease population. Both Pearson’s goodness of fit 
and log likelihood x2 tests show that the Diverticular disease population deviates 
from HWE with respect to p53R2 C>G 4696 although the exact test does not 
replicate this finding.
The student control population and CRC study population were both in HWE with 
respect to both study SNPs.
4.10.2 INBREEDING COEFFICIENTS.
4.10.2.1 Reprimo G>C 824.
Population F value
Student 0.04
Diverticular disease -0.34 
Colorectal cancer -0.19
Table 4.9: Inbreeding coefficients, Reprimo G>C 824.
The positive F value seen in the student population suggests heterozygote 
deficiency the negative values in the DD and CRC populations suggest 
heterozygote excess. This result is supported by the observed genotype frequencies 
and those expected according to the Hardy-Weinberg law.
4.10.2.2 P53R2 C>G 4696.
Population F value
Student 0.13
Diverticular disease 0.48
Colorectal cancer 0.08
Table 4.10: Inbreeding coefficients,p53R2 C>G 4696.
All three populations show positive inbreeding coefficients and therefore 
heterozygote deficiency, again shown by the observed and expected genotype 
frequencies.
4.10.3 TESTS FOR DISEASE -  SNP ASSOCIATION.
4.10.3.1 Reprimo G>C 824.
The results of the Reprimo G>C 824 -  CRC association tests using the DD 
population as control do not suggest any association between the disease and the 
SNP (Table 4.11).
TESTS FOR REPRIMO G>C 824 - COLORECTAL CANCER
ASSOCIATION 
(Diverticular disease control population)
Allele
frequency
difference
Heterozygous Homozygous
Allele
positivity
Armitage’s 
Trend test
Ris i allele -  C
O.R.=1.50 
C.I.=0.92-2.41 
X2=2.58 
p=0.11 (P)
O.R=1.24
C.I.=0.49-3.15
r= o .2 i
p=0.64
O.R=2.90 
C.I.=0.88- 
9.23 
^=3.18
p=0.08
O.R=1.52
C.I.=0.61-
3.76
X2=0.83
p=0.36
O.R.=1.70
X2=3.37
p=0.07
Ris k allele -  G
O.R. = 0.67 
C.I.= 0.42-1.092 
X2=2.58 
p=0.11 (P)
O.R. = 0.44 
C.I.= 0.17- 
1.11 
X2=3.11
p=0.08
O.R.= 0.35 
C.I.=0.11- 
1.13 
X2=3.18
p=0.08
O.R =0.42 
C.I.=0.17- 
1.04 
X2=3.65
p=0.06
O.R. = 0.59
X2=3.37
p=0.07
Table 4.11: Reprimo G>C 824 - CRC association tests using diverticular disease control 
population (O.R., odds ratio; C.L, confidence interval).
TESTS FOR REPRIMO  G>C 824 - COLORECTAL CANCER
ASSOCIATION 
(Student control population)
Allele
frequency
difference
Heterozygous Homozygous
Allele
positivity
Armitage’s 
Trend test
Itisk allele -  C
O.R. =1.40 
C.I.=0.94-2.09 
X2=2.76 
p=0.10(P)
O.R. =2.47 
C.I.=1.15-5.29 
X2=5.54
p=0.02
O.R. =2.24 
C.I.=0.95- 
5.28 
X2=3.46
p=0.06
O.R. =2.39 
C.I.=1.15- 
4.96 
X2=5.66
p=0.02
O.R. =1.47 
X2=2.93 
p=0.09
I Ask allele -  G
O.R. =0.71 
C.I.=[0.48-1.06] 
X2=2.76 
p=0.10(P)
O.R. =1.10 
C.I.=[0.56- 
2.16] 
X2=0.08
p=0.78
O.R. =0.45 
C.I.=[0.19- 
1.05] 
X2=3.46
p=0.06
O.R. =0.86 
C.I.=[0.45- 
1.63]
X2=0.21
p=0.64
O.R. =0.69 
X2=2.93 
p=0.09
Table 4.12: Reprimo G>C 824 - CRC association tests using student control population (O.R.,
odds ratio; C.I., confidence interval).
The heterozygous and allele positivity tests suggest association with CRC with 
respect to the C allele. Otherwise no other disease association between Reprimo 
G>C 824 and CRC is detected when the student population is used as the control 
(Table 4.11).
P53R2 C>G 4696.
TESTS FOR P53R2 C>G 4696- COLORECTAL CANCER
ASSOCIATION 
(Diverticular disease control population)
Allele
frequency
difference
Heterozygous Homozygous
Allele
positivity
Armitage’s 
Trend test
Elisk allele -  C
O.R. = 0.54 
C.I.=0.17-1.67 
X2=1.19
p=0.28 (P)
O.R. = 6.00 
C.I.=0.26- 
140.05 
r= i.47  
p=0.23
O.R. = 1.78 
C.I.=0.11- 
29.18 
X2=0.17
p=0.68
O.R. = 1.96 
C.I.=0.12- 
32.00 
^=0-23 
p=0.63
O.R. = 0.75 
X2=1.02 
p=0.31
Elisk allele -  G
O.R. =1.87 
C.I.=0.60-5.84 
)C2=1.19 
p=0.28 (P)
O.R. =3.37 
C.I.=0.72- 
15.70 
X2=2.64
p=0.10
O.R. =0.56 
C.I.=0.03- 
9.18 
X2=0.17
p=0.68
O.R. =2.43 
C.I.=0.66- 
8.98 
X2=1.87 
p=0.17
O.R. =1.43
X2=1.02
p=0.31
Table 4.13: p53R2 C>G 4696 - CRC association tests using diverticular disease control 
population (O.R., odds ratio; C.I., confidence interval).
No disease association is detected when using the diverticular disease population as 
control (Table 4.12).
TESTS FOR P53R2 C>G 4696- COLORECTAL CANCER
ASSOCIATION 
(Student control population)
Allele
frequency
difference
Heterozygous Homozygous
Allele
positivity
Armitage’s 
Trend test
I 'Ask allele -  C
O.R. =1.25 
C.I.=0.61-2.57 
x2=0.37 
p=0.54(P)
O.R. =1.60 
C.I.=0.13- 
19.84 
X2=0.14 
p=0.71
O.R. =1.86 
C.I.=0.17- 
20.94 
X2=0.26 
p=0.61
O.R. =1.83 
C.I.=0.16- 
20.46 
X2=0.25
p=0.62
O.R. =1.25 
X2=0.34 
p=0.56
FAsk allele -  G
O.R. =0.80 
C.I.=0.39-1.64
X2=0.37
p=0.54(P)
O.R. =0.86 
C.I =0.38-1.94 
X2=0.13 
p=0.71
O.R. =0.54 
C.I.=0.05- 
6.03
X2=0.26 
p=0.61
O.R. =0.82 
C.I.=0.38- 
1.79 
X2=0.25
p=0.62
O.R. =0.80 
X2=0.34 
p=0.56
Table 4.14: p53R2 C>G 4696 - CRC association tests using student control population (O.R., 
odds ratio; C.I., confidence interval).
No disease association is detected when using the student population as control 
(Table 4.13).
4.11 SUMMARY OF RESULTS.
A total of 255 individuals were genotyped for the Reprimo G>C 824 and p53R2 
C>G 4696 SNPs. The individuals came from three populations; a colorectal cancer 
(CRC) study population (n=96) and two control populations; a diverticular disease 
(DD) age matched population (n=52) and an unmatched student (ST) population 
(n=107).
The DNA collection and isolation method was effective and yielded sufficient DNA 
to perform genotyping of 96% of individuals in the study. The genotyping 
technique was validated by replication and by independent laboratory sequencing of 
representative samples of all SNP genotypes of both genes.
The Reprimo G>C 824 genotype frequencies in the CRC population were 14%GG, 
58%GC and 28% CC. In the DD population -  19% GG, 67% GC and 14% CC and 
in the ST population 28% GG, 47% GC and 25% CC. The Reprimo G>C 824 allele 
frequencies in the CRC population were G -  43% and C -  57%, in the DD 
population G -  53% and C -  47% and in the ST population G -  51% and C -  49%. 
The p53R2 C>G 4696 genotype frequencies in the CRC population were 1%GG, 
13%GC and 86% CC. In the DD population- 2% GG, 4% GC and 94% CC and in 
the ST population 2% GG, 16% GC and 82% CC. The p53R2 C>G 4696 allele 
frequencies in the CRC population were G -  7% and C -  93%, in the DD 
population G -  4% and C -  96% and in the ST population G -  9% and C -  91 %.
All populations were in Hardy-Weinberg equilibrium with respect to both study 
SNPs except for the diverticular population with respect to Reprimo G>C 824, 
where an excess of heterozygotes was observed.
Heterozygous and allele positivity association tests detected a statistically 
significant association between the C allele of Reprimo G>C 824 and CRC when 
using the unmatched student population as a control. However the other association
tests did not detect any disease association with either the DD or ST population 
controls.
No association was detected between the p53R2 C>G 4696 SNP and CRC with any 
association test or with either the DD or ST control populations.
The significance of these results will be discussed in detail in the next chapter.
Chapter 5
DISCUSSION
This chapter will discuss the results presented in chapter 5 in the context of what 
can be concluded about any association between the Reprimo G>C 824 and p53R2 
C>G 4696 SNPs with CRC and how the results compare with existing knowledge 
regarding the SNPs. The work as a whole will be discussed in terms of the study 
design and methodology in the context of similar studies and guidelines for such 
studies, paying attention to the strengths and weaknesses of the study. Finally there 
will be a discussion regarding further work that could follow on from this study.
In the past ten years there has been an explosion of SNP-disease association studies 
stimulated by the Human Genome Project and technological developments allowing 
increasingly rapid identification of SNPs. Paralleling these advances has been the 
refining of genetic association studies in terms of their methodology, analysis and 
reporting. This has lead to the publication of guidance and check-lists with the aim 
of increasing the reliability and veracity of such studies (Becker et al., 2003, 
Campbell and Rudan, 2002, Hattersley and McCarthy, 2005a, Silverman and 
Palmer, 2000, Cooper et al., 2002, Lewis, 2002a, Daly, 2003, Cordell and Clayton, 
2005). These publications also allow readers to be able to critically appraise SNP 
association studies.
5.1 GENERAL DISCUSSION OF RESULTS.
The aim of the study was to investigate disease association between two SNPs 
(Reprimo G>C 824 and p53R2 C>G 4696) and CRC by means of a case-control 
study. The methodology reliably identified the two SNPs and three populations
(CRC study population, diverticular disease control population and young, healthy 
control population) were genotyped with respect to the two SNPs. The data 
collected from the study were analysed using an on-line statistical calculator 
designed for SNP studies. This analysis involved testing each population for HWE 
(HWE) and allelic and genotypic association, taking into account the possible 
different models of gene penetrance. The results showed that all populations were in 
HWE with respect to both SNPs except for the diverticular disease population with 
respect to the Reprimo 824 C>G SNP, where an excess of heterozygotes was 
demonstrated. Deviation from HWE can be due to disease association and therefore 
this result may be interpreted as a positive association between heterozygotes for 
Reprimo G>C 824 and diverticular disease. Disease association tests did not show 
any significant association between p53R2 C>G 4696 and CRC and so it may be 
concluded from these results that the p53R2 C>G 4696 SNP has not been found to 
be associated with CRC in this study. An association between the C allele of the 
Reprimo G>C 824 SNP and CRC was demonstrated when heterozygous and allele 
positivity association tests were performed using the un-matched, young, healthy 
population as a control. On face value it would appear that there is an association of 
the C allele with CRC; however the interpretation of this result is not straight 
forward, as the populations are not matched and there was no similar association 
shown when testing with a matched control. This will be discussed further below.
5.1.2 Deviation from HWE with respect to Reprimo G>C 824.
The Diverticular disease population was shown to be in deviation from HWE with 
respect to the Reprimo G>C 824 SNP, with an excess of heterozygotes and lack of 
both G and C homozygotes. The usual causes of deviation from HWE, inbreeding, 
genetic drift, small population size and selection pressure (Connor and Ferguson-
Smith, 1993) cannot explain this finding in a large, randomly mating, static and late 
onset disease population. Deviation from HWE may also be due to genotyping 
errors, population stratification or chance (Silverman and Palmer, 2000, Wittke- 
Thompson et al., 2005a), however genotyping was shown to be accurate by 
independent laboratory sequencing of DNA and the sample was ethnically 
homogenous. The relatively small sample size does increase likelihood that HWE 
deviation is due to chance (Campbell and Rudan, 2002) and this must be considered 
in this case.
However if none of these factors are causing the deviation from HWE seen in the 
Diverticular disease population it may be due to genetic association (Balding et al.,
2001). The nature of this association is obscure, however. It is also unusual in that 
the heterozygote genotype appears to be associated with the diverticular disease 
phenotype. Heterozygotes have been shown to alter gene function (Richmond and 
Powell, 1970) and survival advantage due to increased heterozygote fitness is 
termed heterosis, however diverticular disease does not affect biological fitness. 
The dominant negative effect seen in p53, where mutant gene products derived 
from the mutant allele form dysfunctional protein complexes with wild type 
proteins, is well recognised. However this study suggests both the GG and CC 
homozygotes function normally and it is the combination of the G and C alleles in 
the heterozygote that is associated with the diverticular disease phenotype.
This association would support the possibility that SNPs occurring in non-coding 
regions can modulate gene function, a phenomenon that has been demonstrated by 
3’UTR TAF1 gene polymorphisms (Henry et al., 2001). In terms of possible 
biological mechanisms resulting in this association the Reprimo gene may have an 
as yet undiscovered pleiotropic function other than cell cycle control or Reprimo 
824G>C heterozygotes may be less able to repair DNA damage from reactive 
oxygen species produced in inflammation in diverticulitis. Clearly more work is
required to investigate this finding, both from a population genetics and molecular 
pathological perspective.
5.1.3 Association between the Reprimo G>C 824 C allele and CRC.
When the student population was used as a control, an association was detected 
between the Reprimo G>C 824 C allele and CRC on heterozygous and allele 
positivity tests. These tests assume no specific genotype relationships or a dominant 
or recessive penetrance model. It has been demonstrated that SNP-disease 
associations may only be detected by %2 tests using different contingency Tables to 
account for different models of genetic penetration (Ohashi et al., 2001), and so the 
results may be considered significant. However, the same result was not found 
when association testing was performed using the diverticular disease control 
population, which was matched for age and ethnicity. Indeed when ethnic groups 
other than Caucasian are excluded from the student population and the association 
tests performed, no association is detected. Therefore association of the C allele of 
the Reprimo G>C 824 with CRC should be considered as a type I error, likely due 
to ethnic bias. Ethnicity matching in genetic case-control studies will be discussed 
below.
5.2 DISCUSSION OF THIS WORK IN THE CONTEXT OF SIMILAR 
STUDIES.
5.2.1 Reprimo G>C 824 and p53R2 C>G 4696 studies.
The SNPs studied in this work were originally described by Ye and Parry (Ye and 
Parry, 2002b, Ye and Parry, 2002a). They found the genotype frequencies of the
Reprimo G>C 824 SNP to be CC 41.5%, GC 40.2% and GG 18.3% and of the 
p53R2 G>C4696 SNP to be CC 73%, GC 23% and GG 4% in 82 healthy 
individuals (average age 43.5, 47 women and 35 men). The populations were in 
HWE. The ethnicity of the sample is not given, nor was it indicated whether the 
genotype frequencies were checked. These frequencies are not significantly 
different from the genotype frequencies found in the student population in this 
study, but are significantly different from the diverticular disease and CRC 
populations with respect to Reprimo G>C 824, (x2 tests: diverticular disease 
population; p<0.01, CRC population; p< 0.01) and from the diverticular population 
with respect to p53R2 C>G 4696 (p=0.01). These differences may be due to 
population stratification due ethnicity or age differences (discussed below) or due to 
genotyping errors in Ye and Parry’s samples. If Ye and Parry’s samples are used as 
controls to the CRC cases in this study then disease-gene associations are detected 
between both the Reprimo G>C 824 and p53R2 C>G 4696 SNPs. Similarly if  Ye 
and Parry’s samples are pooled with the student population used in this study (with 
which the genotype frequencies are similar) association is detected between 
Reprimo G>C 824 and CRC. However, these findings should be interpreted with 
caution due to potential population stratification in unmatched populations.
That significant differences in the genotype frequencies between Ye and Parry’s 
studies and that three of the five SNPs reported in Ye and Parry’s studies were not 
detected in this study (see preliminary work) demonstrates the difficulty of 
reproducing results of SNP studies (Ioannidis et al., 2001). The reasons for non­
replication of the findings of gene-disease studies are varied, but include variations 
in study design, variations in relative risk of the candidate genes in different 
populations, the genetic complexity of complex diseases and selection of 
polymorphisms which are not causal (Tabor et al., 2002).
There are no published studies of either Reprimo G>C 824 or p53R2 G>C 
association studies with either CRC, diverticular disease or any other diseases.
5.2.2 Other Reprimo andp53R2 SNP studies.
Other than the papers by Ye and Parry, there are no other published papers 
describing Reprimo SNPs. In their paper Ye and Parry describe two Reprimo SNPs, 
the G>C 824 and C>G 839. As described previously it was not possible to 
demonstrate the Reprimo C>G 839 SNP despite altering the conditions as described 
by Ye and Parry. Similarly two other p53R2 SNPs as described by Ye and Parry 
were not detected.
Including the SNPs described by Ye and Parry, seven p53R2 SNPs have been 
described (Smeds et al., 2001, Ye and Parry, 2002a, Deng et al., 2005). Of these 
three have been tested for disease association with the colorectal adenomas, CRC 
precursor lesions (Deng et al., 2005). In that study no association was found 
between colorectal adenomas and a C>G 789 transversion, a G>A 928 transition or 
a T>C 933 transition.
Therefore although they are reasonable candidates for CRC association studies, 
there is, as yet, no evidence to support Reprimo and p53R2 SNPs influencing the 
risk of developing CRC.
5.3 DISCUSSION OF THE STUDY DESIGN AND METHODOLOGY.
5.3.1 Population selection and matching.
5.3.1.1 Cases.
The cases used in this study were sampled from patients known to have CRC. The 
patients were recruited into the study at varying times from their diagnosis, i.e. they 
were prevalent cases. Ideally cases should be incident, that is recruited at diagnosis, 
to avoid selection bias (Vineis and McMichael, 1998). Also the cases recruited were 
mostly those with potentially curable stage disease at diagnosis and so represented a 
selected sample, missing those with advanced disease at diagnosis and those with 
very rapid progressive disease. In order to have had only incident cases recruitment 
would have needed to be more targeted and therefore logistically more complex. 
This would have made collecting sufficient samples within the time frame of the 
study period difficult. Also there are ethical issues with recruiting patients at the 
time of their diagnosis of cancer.
5.3.1.2 Control populations.
Two control populations were used in this study; a young, healthy student 
population and a diverticular disease population. The young, healthy student 
population was not matched for age or ethnicity with the cases and as such 
introduces the possibility of confounding due to population stratification and 
selection bias due to age differences (Vineis and McMichael, 1998, Campbell and 
Rudan, 2002). However the population was convenient and it was possible to 
collect tissue samples for genotyping rapidly.
The diverticular disease population was matched for age and ethnicity, but the 
gender distribution was different from the cases, there being a higher proportion of 
women in the diverticular population. Men are known to be at greater risk of CRC 
than women and so the gender difference is a possible source of selection bias. 
Further selection bias could have been introduced as all the diverticular disease 
patients were recruited from a population of hospital patients and as such they 
would have had symptomatic disease (Vineis and McMichael, 1998),(Potter, 2003). 
Most people with diverticulosis, i.e. the asymptomatic phenotype, do not require 
hospital treatment and so recruiting only hospital patients selects those with more 
severe forms of the disease. As with the CRC population, avoiding these biases 
would have made collecting the samples more difficult, and indeed it was only 
possible to collect a relatively small sample within the time frame of the study 
period.
5.3.2 Sample sizes.
Perhaps the greatest weakness of this study is the small size of the population 
samples used leading to a lack of statistical power. Statistical power refers to the 
ability of a study to eliminate type I, false positive, and type II, false negative, 
errors. Conventionally the ideal type I, a, level should be 0.05 and the type II, p, 
level 0.1. No formal power calculations were performed in the initial study design 
in order to determine sample sizes, rather previously similar studies were examined 
and it was decided to use similar sized population samples. It was also felt that it 
would only be possible to collect and analyse samples of around 100 individuals 
within the time frame of the study.
In order to detect susceptibility genes with low relative risks large sample sizes are 
required (Hattersley and McCarthy, 2005a, Becker et al., 2003, Dahlman et al.,
2002). The sample sizes used in this study are only likely to be able to identify 
significant associations for susceptibility alleles with odds ratios greater than four 
and frequencies of greater thanl0% with a and p levels of 0.05 and 0.1 respectively.
5.3.3 DNA collection.
The DNA used for genotyping the populations in this study was isolated from 
buccal cells obtained by brush biopsy. This proved an efficient, reliable and well 
tolerated method of obtaining adequate DNA for analysis and would be 
recommended for further studies.
5.3.4 DNA isolation.
The method used to isolate DNA from the tissue samples proved efficient and 
yielded more than adequate quantities of DNA for genotyping both SNPs, repeat 
genotyping where necessary and to obtain independent laboratory genotyping.
5.3.5 Genotyping.
The preliminary work performed for this study indicates the difficulty in 
reproducing genotyping methods. Only two of the five SNPs described by Ye and 
Parry, Reprimo G>C 824 and p53R2 C>G 4696, were successfully identified, one 
with altered PCR conditions. For one of the other SNPs, Reprimo G>C 839, it was 
not possible to optimize the genotyping conditions to give reliable results. For 
p53R2 A>C 2752 the entire student population was genotyped as AA, and the C 
allele was not detected. Ye and Parry reported an AA frequency of 1% and a CC 
frequency of 89%. Optimisation experiments were not able to detect the C allele.
Similarly it was not possible to detect the G allele of p53R2 A>G 2759. Genotyping 
errors are a common source of errors in genetic disease association studies and may 
lead to spurious associations (Hattersley and McCarthy, 2005a, Hosking et al., 
2004a). Clues to genotyping errors may be given by unexpected results, lack of 
reproducibility or deviation from HWE and should prompt attempts to exclude 
genotyping errors, and bias, from the data (Ioannidis et al., 2001). In this study the 
diverticular population was found to be deviating from HWE and genotyping error 
was suspected. Therefore many of the samples from all three populations were re- 
genotyped for Reprimo G>C 824 and were also genotyped for both Reprimo G>C 
824 and p53R2 C>G 4696 by an independent laboratory. The results indicated that 
the genotyping that there was possibly a 5% error rate for the Reprimo G>C 824 
allele specific PCR. Only 18 samples were sent for independent analysis, due to 
cost restraints, and so although the samples sent were correctly genotyped, errors in 
the rest of the samples could not be discounted. Therefore in interpreting the results 
of this study genotyping errors need to be considered.
5.3.6 Statistical methods.
The statistical methods employed in this study were straight forward and facilitated 
by the use of an on-line calculator specifically designed for SNP-disease association 
analysis. The calculator tests the population samples for HWE and disease- 
association based on various genetic models. As discussed above HWE testing is 
important to detect genotyping errors and may be used as an association test in itself 
(Balding, 2006). HWE was tested using three statistical tests in order to avoid 
confounding due to small sample sizes and small SNP frequencies. The effect of 
small SNP frequency on the results of the HWE tests can be seen in the results for 
p53R2 C>G 4696 where there are differences in the p values of the three tests. In
this case the log likelihood ratio test is the most accurate as the p53R2 C>G 4696 
rare allele was found to occur at 4%-9%. The extent of deviation from HWE, if 
present, was indicated by the inbreeding coefficient test and is used to support the 
tests for HWE (Salanti et al., 2005). Allele and genotype % and odds ratio 
association tests are important in order not to miss associations with differing 
genetic models of penetrance, when this is not known for the study SNP (Lewis, 
2002a, Ohashi et al., 2001). The Armitage’s test for trend had particular utility in 
this study as it is the preferred test when populations deviate from HWE, as was the 
case with the diverticular disease population (Slager and Schaid, 2001b, Balding, 
2006).
Therefore in terms of the nature of this study the statistical methods employed are 
appropriate and robust enough to detect disease association in the event of various 
different genetic situations. However the interpretation of those results needs 
caution due the lack of statistical power and possible sources of bias and 
confounding as discussed previously.
5.4 IMPROVEMENTS THAT COULD BE MADE TO THIS STUDY.
5.4.1 Statistical power.
The fundamental weakness of this study is the small sample sizes leading to low 
statistical power and the increased likelihood of type I error. Therefore the most 
important improvement would be to repeat the study with larger sample sizes based 
on power calculations. Using the Power for Association With Error (P.A.W.E) on­
line calculator (http://linkage.rockerfeller.edu/Dawe/pawe.cgi) the minimum sample 
sizes necessary would be around 2000 for p53R2 C>G 4696 and 300 for Reprimo 
G>C 824 with a significance level of 0.05 and a power of 0.8. This programme
1 zu
takes into account genotyping errors and adjusts the sample sizes necessary in order 
to maintain statistical power (Gordon et al., 2002a). However, collecting sample 
populations of this size would have been beyond the scope of this study.
5.4.2 Avoiding selection bias and confounding.
Selection bias and confounding could be reduced if only incident CRC cases were 
recruited and by recruiting unselected controls, this would be difficult to achieve 
using diverticular disease as a control population as most people with diverticulosis 
are asymptomatic. Therefore the control population should ideally be age and 
gender matched healthy individuals randomly sampled from the community.
5.5 FURTHER WORK STIMULATED BY THIS STUDY.
Although this study lacks statistical power and is prone to selection bias and 
confounding, questions are stimulated and further work prompted.
5.5.1 Repeating the study with greater power and avoiding bias.
The SNPs studied are reasonable candidate genes for CRC association studies and it 
would be useful to repeat the study with the improvements as outlined above, 
although this would be more difficult for a single handed investigator with limited 
time. However robust studies investigating the candidate disease SNPs are needed 
in order to understand the genetic susceptibility to CRC (Houlston and Tomlinson, 
2001).
5.5.2 Investigating the association between Reprimo G>C 824 and 
diverticular disease.
The deviation from HWE seen in the diverticular disease population should be 
investigated firstly by genotyping a larger sample. If HWE deviation is seen in an 
adequately sized sample to give good statistical power then a well designed and 
conducted case-control disease association study should be performed. If 
diverticular disease is shown to have a molecular pathology it may become possible 
to identify genotypes that confer a greater risk developing complications, and so 
allowing targeted management strategies for different individuals.
5.5.3 Searching for further Reprimo andp53R2 SNPs.
The SNPs studied in this study both occur in the 3’-UTR, a region thought less 
likely to affect gene function through polymorphisms (Tabor et al., 2002). Coding 
sequence SNPs are much more likely to have effects on gene function, therefore a 
search of the coding regions of Reprimo and p53R2 should be prioritized in any 
search for further SNPs.
5.5.4 Reprimo and p53R2 SNP interaction analysis.
As the aetiology of complex diseases such as CRC is thought to involve gene-gene, 
as well as gene-environment, interactions, investigating disease associations should 
extend beyond single candidate gene association to multiple polymorphisms 
(Goodman et al., 2006). Therefore further investigation into Reprimo and 53R2 
association should involve multiple candidate genes and environmental factors.
5.5.5 Functional analysis of Reprimo G>C 824 and p53R2 C>G 4696 SNPs.
Investigating the effects of DNA damaging agents on cells of known genotype 
would give valuable information as to any functional polymorphic variation. Such 
experiments would involve exposing cell cultures from individuals of known 
genotypes to various genotoxic agents and observing for differences in DNA 
damage, chromosomal damage and apoptosis.
5.6 SUMMARY.
Reprimo G>C 824 deviation from HWE seen in the diverticular disease population 
may be due to chance, which is more likely with the small sample size, or disease 
association. Disease association is difficult to explain, both from a mechanistic 
point of view in the light of the current understanding of the pathogenesis of 
diverticular disease, and from a genetic point of view as the disease association is 
with the heterozygote.
The CR.C-p53R2 C>G 4696 association seen on heterozygous and allele positivity 
testing, using the student population as a control, is likely due to different 
population sample ages and ethnic mix confounding and small sample sizes leading 
to weak statistical power.
The strengths of this study lie in the methods for collecting tissue samples using 
buccal brush biopsy, the efficient and high yielding DNA isolation technique, the 
effective genotyping method with a reasonable error rate and the use of on-line 
statistical software specifically designed for SNP studies.
The weaknesses are the potential for selection bias in the case samples due 
recruiting prevalent cases, confounding due age, gender and ethnic heterogeneity in
the control and case populations and small sample sizes leading to a statistically 
weak study.
The study does prompt further work: repeating the study with a more robust design 
to eliminate bias, confounding and increase statistical power; investigating the 
Reprimo G>C 824 -  diverticular disease association; investigating other Reprimo 
and p53R2 SNPs; functional studies of the polymorphisms and Reprimo and p53R2 
SNP interaction analysis.
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APPENDIX A: PATIENT INFORMATION SHEETS 
Appendix A1
INFORMATION SHEET FOR COLORECTAL CANCER PATIENTS
Contact: Dr William Beasley, Research Registrar, Singleton Hospital.
BOWEL CANCER GENETICS RESEACH
p53R2 and Reprimo gene single nucleotide polymorphism frequencies in 
random, diverticular disease and colorectal cancer populations.
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. Ask us if there is anything that is 
not clear or if you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical 
Research and You’. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from 
CERES, P.O. Box 1365, LONDON N16 OBW.
Thank you for reading this.
What is the purpose of the study?
We know that cancer develops due to damaged DNA within cells and that in some 
cases the risk of developing bowel cancer is inherited due to defective genes being 
passed from generation to generation.
The aim of this study is to see whether different forms of two newly discovered 
genes, p53R2 and Reprimo, influence a persons risk of developing bowel cancer.
The results of the research may be used, together with other information, to screen 
people for bowel cancer and help to catch the disease at an early, curable stage.
It should take two years to complete the research and we will need to collect DNA 
samples from around two hundred people.
I^ U
INFORMATION SHEET FOR COLORECTAL CANCER PATIENTS
Why have I been chosen?
As someone who has had bowel cancer, we are interested to see what forms of the 
two genes, p53R2 and Reprimo, you have and whether people who develop bowel 
cancer have different forms of the genes from people who do not develop bowel 
cancer.
Do I have to take part?
Your taking part in this research is entirely voluntary. If you decide to take part you 
will be given this information sheet to keep. This will not affect the standard of care 
you receive.
What will happen to me if I take part?
All we ask of you is to let us take a sample of cells from the inside of your cheek 
using a special brush. We will do this before you go home after your appointment; 
it takes no more than a couple of minutes to collect the sample.
We will also collect a few details about you and your diagnosis from your hospital 
records. These details will be kept confidential.
The sample you give will be analyzed to see what forms of the genes you have. 
Once we have collected enough samples from different people who do and do not 
have bowel cancer we will be able to compare the results to see whether the 
different forms of the genes affect peoples’ risk of developing bowel cancer.
How will the results affect me?
The results of this research will not affect any subsequent treatment you may need. 
However the results may help us to treat future patients with bowel cancer.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information about you that leaves the hospital will 
have your name and address removed so that you cannot be recognized from it.
INFORMATION SHEET FOR COLORECTAL CANCER PATIENTS
What will happen to the results of the research?
The research is being conducted as part of a Master of Surgery Degree by Dr. 
William D Beasley and will be used to produce a thesis.
The results may also be published in medical or scientific journals.
Who is organizing and funding the research?
The research is being organized and funded by Dr William D Beasley, with support 
from the colorectal surgery department, Singleton Hospital, and the Centre for 
Molecular Genetics and Toxicology, School of Biological Sciences, University of 
Wales, Swansea.
Additional funding has been applied for in the form of a Surgical Research 
Fellowship from the Royal College of Surgeons of England.
Who has reviewed the research?
The Iechyd Morgannwg Health Local Research Ethics Committee has reviewed the 
research.
Thank you for taking the time to read this letter and taking part in this research.
Appendix A2
INFORMATION SHEET FOR DIVERTICULAR DISEASE PATIENTS
Contact: Dr William Beasley, Research Registrar, Singleton Hospital.
BOWEL CANCER GENETICS RESEACH
p53R2 and Reprimo gene single nucleotide polymorphism frequencies in 
random, diverticular disease and colorectal cancer populations.
NB: WE WOULD LIKE TO MAKE IT CLEAR THAT THERE IS NO 
SUSPICION THAT YOU HAVE BOWEL CANCER.
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. Ask us if there is anything that is 
not clear or if  you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical 
Research and You’. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from 
CERES, P.O. Box 1365, LONDON N16 OBW.
Thank you for reading this.
What is the purpose of the study?
We know that cancer develops due to damaged DNA within cells and that in some 
cases the risk of developing bowel cancer is inherited due to defective genes being 
passed from generation to generation.
The aim of this study is to see whether different forms of two newly discovered 
genes, p53R2 and Reprimo, influence a persons risk of developing bowel cancer.
The results of the research may be used, together with other infoimation, to screen 
people for bowel cancer and help to catch the disease at an early, curable stage.
It should take two years to complete the research and we will need to collect DNA 
samples from around two hundred people.
INFORMATION SHEET FOR DIVERTICULAR DISEASE PATIENTS
Why have I been chosen?
You have been diagnosed as having diverticular disease. This is thought to develop 
partly due to lack of fibre in the diet. A lack of fibre is also thought to increase the 
risk of developing bowel cancer. People also tend to develop diverticular disease at 
the same age as those who develop bowel cancer, and tend to live in the same areas.
However having diverticular disease does not increase your risk of developing 
bowel cancer.
We want to see whether this difference is due to people with diverticular disease 
and people with bowel cancer having different forms of the genes p53R2 and 
Reprimo.
Do I have to take part?
Your taking part in this research is entirely voluntary. If you decide to take part you 
will be given this information sheet to keep. This will not affect the standard of care 
you receive.
What will happen to me if I take part?
All we ask of you is to let us take a sample of cells from the inside of your cheek 
using a special brush. We will do this before you go home after your appointment; 
it takes no more than a couple of minutes to collect the sample.
We will also collect a few details about you and your diagnosis from your hospital 
records. These details will be kept confidential.
The sample you give will be analyzed to see what forms of the genes you have. 
Once we have collected enough samples from different people who do and do not 
have bowel cancer we will be able to compare the results to see whether the 
different forms of the genes affect peoples’ risk of developing bowel cancer.
How will the results affect me?
The results of this research will not affect any subsequent treatment you may need. 
However the results may help us to treat future patients with bowel cancer.
INFORMATION SHEET FOR DIVERTICULAR DISEASE PATIENTS
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information about you that leaves the hospital will 
have your name and address removed so that you cannot be recognized from it.
What will happen to the results of the research?
The research is being conducted as part of a Master of Surgery Degree by Dr. 
William D Beasley and will be used to produce a thesis.
The results may also be published in medical or scientific journals.
Who is organizing and funding the research?
The research is being organized and funded by Dr William D Beasley, with support 
from the colorectal surgery department, Singleton Hospital, and the Centre for 
Molecular Genetics and Toxicology, School of Biological Sciences, University of 
Wales, Swansea.
Additional funding has been applied for in the form of a Surgical Research 
Fellowship from the Royal College of Surgeons of England.
Who has reviewed the research?
The Iechyd Morgannwg Health Local Research Ethics Committee has reviewed the 
research.
Thank you for taking the time to read this letter and taking part in this research.
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CONSENT FORM FOR COLORECTAL CANCER POPULATION.
Patient identification number for this trial............
N.B. Three copies should be made for (1) patient, (2) researcher, (3) hospital notes
Title of project :p53R2 and Reprimo single nucleotide polymorphisms 
random, diverticular disease and colorectal cancer populations.
Name of researcher :Dr William D Beasley
Contact telephone number:01792 205666
Please
initial
Box.
1. I confirm that I have read and understood the information sheet
for the above study and have had the opportunity to ask questions. I
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked 
at by the research team or from regulatory authorities where it is 
relevant to my taking part in research. I give permission for these 
individuals to have access to my records
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
Appendix B2
CONSENT FORM FOR DIVERTICULAR DISEASE POPULATION.
Patient identification number for this trial...............................
N.B. Three copies should be made for (1) patient, (2) researcher, (3) hospital notes
Tide of project :p53R2 and Reprimo single nucleotide polymorphisms in random, 
diverticular disease and colorectal cancer populations.
Name of researcher : Dr William D Beasley
Contact telephone number:01792 205666
Please
initial
box.
1. I confirm diat I have read and understood the information sheet
for die above study and have had the opportunity to ask questions. I
2. I understand diat my participation is voluntary and that I am free 
to withdraw at any time, widiout giving any reason, widiout my 
medical care or legal rights being affected.
3. I understand diat sections of any of my medical notes may be looked 
at by the research team or from regulatory audiorities where it is 
relevant to my taking part in research. I give permission for diese 
individuals to have access to my records
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
APPENDIX C: PUBLICATIONS ARISING FROM THIS STUDY 
Appendix C l 
PEER REVIEWED PAPER
Published in the International Journal of Colorectal Disease, volume 23, number 4,
April 2008.
DOI: 10.1007/s00384-007-0435-3
The original publication is available at www. snringerlink. com
Reprimo 824 G>C and p53R2 4696 C>G Single Nucleotide 
Polymorphisms and Colorectal Cancer: A Case -  Control Disease
Association Study.
William D Beasley (Corresponding author), Department of Colorectal Surgery, 
Singleton Hospital, Swansea NHS Trust Sketty, Swansea, SA2 8QA, Wales and 
Centre for Molecular Genetics and Toxicology, School of Biological Sciences, 
University of Wales Swansea, Singleton Park, Swansea SA2 8PP, Wales. E-mail: 
williamdbeaslev@hotmail.com
John Beynon, Department of Colorectal Surgery, Singleton Hospital, Swansea NHS 
Trust Sketty, Swansea, SA2 8QA, Wales. E-mail: iohnbeynon56@hotmail.com,
Gareth J S Jenkins, Centre for Molecular Genetics and Toxicology, School of 
Biological Sciences, University of Wales Swansea, Singleton Park, Swansea SA2 
8PP, Wales. E-mail: g.i.ienkins@swansea.ac.uk.
Jim M Parry, Centre for Molecular Genetics and Toxicology, School of Biological 
Sciences, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, Wales. 
E-mail: imp@swan.ac.uk 
Abstract
Background
Improved survival from colorectal cancer (CRC) may result from screening for 
inherited genetic risk factors. Reprimo and p53R2 are p53 inducible genes involved 
in cell cycle surveillance and DNA repair. Single nucleotide polymorphisms (SNPs) 
of these genes have been discovered but their effects on the genes’ function and 
association with CRC is not known.
Methods
90 healthy controls, 52 diverticular disease controls and 96 colorectal cancer cases 
were genotyped. DNA was extracted from buccal brush biopsies. Genotyping was 
performed by polymerase chain reaction (PCR) or polymerase chain 
reaction/restriction fragment length polymorphism (PCR/RFLP) methods. Tests for 
Hardy-Weinberg equilibrium and allelic- and genotype-disease association were 
performed on line using the Finetti program.
Results
All three populations were in Hardy-Weinberg equilibrium with respect to p53R2 
4696C>G SNP and no CRC associations were demonstrated with this SNP. The 
healthy and CRC populations were in Hardy-Weinberg equilibrium with respect to 
the Reprimo 824G>C SNP but the diverticular disease population was not (p=
0.03). No CRC were demonstrated with Reprimo 824G>C.
Conclusion
No association between p53R2 4696C>G or Reprimo 824G>C with colorectal 
cancer was shown by this study. An association between the Reprimo 824G>C 
heterozygote and diverticular disease may exist on the basis of deviation from 
Hardy-Weinberg equilibrium.
Background
Colorectal cancer (CRC) is the second most common cause of death from malignant 
disease accounting for nearly 400,000 deaths per year worldwide [1]. The molecular 
pathology of colorectal carcinogenesis is well understood along the adenoma- 
carcinoma sequence [2, 3], resulting in the development of genetic paradigms 
outlining the fundamental molecular steps along the pathway from normal colonic 
epithelium to adenoma to carcinoma [4-6].
The majority of CRC cases are sporadic [6] and the genetic susceptibility factors 
involved are unknown but it is thought that common, low penetrance genetic 
variants, including SNPs, combined with environmental factors (a western style 
diet rich in red meat and fat and low in fibre and vegetables, obesity and smoking) 
may influence CRC risk and modulate the genetic steps in the adenoma-carcinoma 
sequence [7]. Screening for genetic susceptibility factors could potentially have a 
profound impact on reducing CRC mortality by allowing clinicians to assess 
individual's’ genetic risk of developing CRC and tailoring prevention strategies, 
screening and treatment to the individual.
p53-inducible ribonucleotide reductase small subunit 2 homologue (p53R2) is 
located at chromosome 8q23.1 It is a direct target for the tumour suppressor gene 
p53, and its induction in response to DNA damage assists in G2 arrest and provides
DNA precursors for DNA repair [8, 9]. Dysfunction of p53R2 could result in a 
failure of DNA damage repair and so lead to gene mutation or cellular apoptotic 
activation [10].
Impaired p53R2 induction and RR formation with hRRMl in response to UV has 
been demonstrated in p53 mutant cell lines [11] and studies have suggested a 
possible association of p53R2 with oral carcinogenesis [12].
Three SNPs in the p53R2 gene have been identified with in the 3’ untranslated 
region (UTR) of the gene [13]. The effects of these SNPs on p53R2 function are not 
known but it is easy to see that if they do interfere with function, DNA repair could 
be compromised and therefore would have a potential role in carcinogenesis. An 8 
base pair polymorphism in the 5’ UTR of p53R2 has also been detected but no 
association was found with a variety of cancers [14].
Reprimo is a p53 inducible gene located at chromosome 2q23 [15]. Reprimo 
expression leads to arrest of the cell cycle at G2/M by inhibition of CDK1 activity 
and nuclear translocation of cyclin B1 [16]. Cell cycle arrest at this stage in the cell 
cycle allows repair of damaged DNA or to permanent arrest of severely damaged 
cells. Defective Reprimo function could result in failure to repair DNA damage and 
increased cell proliferation. Lowered Reprimo expression and an increased 
incidence in uterine sarcomas has been shown in p53vall35/wt mice exposed to 1,2 
dimethylhydrazine [17]. Aberrant Reprimo Methylation has been shown in 
pancreatic cancer [18].
Two 3’ UTR SNPs of the Reprimo gene have been identified [19]; It is not known 
whether these polymorphisms have any effect on Reprimo expression or function. 
To date many studies have looked for and identified associations between 
polymorphisms, including SNPs, and CRC [7, 20, 21]. On the basis of the 
understanding of the functions of Reprimo and p53R2 it is biologically reasonable
to select p53R2 and Reprimo polymorphisms as candidates for CRC association 
studies.
This paper presents the results of a population based CRC -  SNP association study 
of Reprimo 824 G>C and p53R2 4696 C>G using a young healthy unmatched 
population and an aged matched diverticular disease control population.
MATERIALS AND METHODS.
Subjects.
Three populations were studied:
1. A healthy young adult control population (N = 90; 60 female, 30 male. 
Average age 19.1 years. Ethnicity: 100% Caucasian).
2. A Diverticular disease, age matched, population. (N = 52; 37 female, 15 
male. Average age 67.5 years. Ethnicity: 100% Caucasian). All had either 
endoscopically or radiographically proven diverticular disease.
3. Colorectal cancer population. (N = 96; 32 female, 64 male. Average age 
68.3 years. Ethnicity: 100% Caucasian). All had histologically proven 
colorectal adenocarcinoma.
All subjects were volunteers and gave fully informed consent to participate in the 
study. Ethical approval was obtained from the local ethics committee.
DNA collection and extraction.
DNA was extracted by standard methods (Puregene™ DNA Purification System, 
Gentra Systems) from buccal cell brush biopsies.
Genotyping.
The Reprimo 824G>C SNP was identified by an allele specific polymerase chain 
reaction (PCR) method. Oligonucleotide primers (Upstream; 5'- 
AGAGGGCGATTAGGGCGCAG-3', 5 '-AGAGGGCGATTAGGGCGCAC-3',
Downstream; 5'-AGGAGAAGAGTGGGAGCGC-3') as described by Ye and Parry 
[19] were used and supplied by MWG. PCR was performed in a PTC-225 Peltier 
Thermal Cycler (MJ research) under the following conditions; five minutes initial 
denaturation at 94°C, followed by 32 cycles of 94°C for 45 seconds, 62°C for 30 
seconds, 72°C for 45 seconds and a five minute final extension at 72°C.
The p53R2 4696 C>G SNP was identified by a polymerase chain reaction/ 
restriction fragment length polymorphism method. The SNP creates a digestion site 
for the Hind III restriction enzyme. Primers (5 '-TT CT GT AC AT GC AGGCTT GG- 
3', 5 '-AGATGGAAGGCTGGGAGAAT-3') were as described by Ye
and Parry [13]. The PCR took place under the following conditions; Five minutes 
initial denaturation at 94°C followed by 32 cycles of 94°C for 10 seconds, 57°C for 
20 seconds and 72°C for 45 seconds and a final extension at 72°C for 5 minutes. 
PCR products were digested with Hind III at 37°C overnight.
The reaction mix used for both genes was; 1.5 mM MgCb, 10 mM Tris-HCl Buffer 
(pH 8.8), 100 pM each dNTP, 100 pmols upstream primer, 100 pmols downstream
primer, 2.5 U Taq DNA Polymerase (Promega corp.), 2 pi template DNA solution 
(average concentration 2.5ng/pl) in a total volume of 50pl.
All PCR and PCR/RFLP products were visualised on a 2.5% agarose gel with 
ethidium bromide staining.
Validating genotyping fidelity.
Samples of PCR products were sent for independent sequencing in order to verify 
the efficacy of the PCR technique.
Statistical analysis.
The SNPs were tested for Hardy-Weinberg equilibrium and genotype and allelic 
disease association on-line using the de Finetti programme [22] accessed via the 
Genestat Statistical Genetics web site[23]. The programme generates expected 
genotype frequencies, allele frequencies and inbreeding coefficient from observed 
genotype frequencies. Deviation from Hardy-Weinberg equilibrium is tested by 
Pearson’s goodness-of-fit, Log likelihood ratio and exact chi-square tests (with 1 
degree of freedom). Tests for association are performed using chi square and odds 
ratio for allele-, heterozygote- and homozygote- frequency differences, allele 
positivity and Armitage’s trend test. The tests were carried out twice for each SNP 
using both control populations. P values of less than 0.05 were significant.
Results
Gel electrophoresis patterns for both SNPs are shown in Figures two and three. 
Reprimo homozygotes are visualised as a single band and heterozygotes as a double 
band, each band representing either the G or C allele. P53R2 GG homozygote PCR 
products do not contain the H i n d  111 digestion site and were not cut, showing as a 
single 228 bp electrophoresis band. P53R2 CC homozygote PCR products contain 
the H i n d  III digestion site and so show as 78bp and 149 bp electrophoresis bands. 
The p53R2 C>G 4696 heterozygotes are represented by three bands, at 228, 149 
and 78 bp.
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Figure 1: Electrophoresis gel visualisation of Reprimo 824G>C genotypes.
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Figure 2: Electrophoresis gel visualisation of p53R2 4696C>G genotypes.
Sequencing of representative PCR product samples from both genes and all 
populations confirmed the techniques to identify the SNPs were specific. 
Chromograms showing the SNPs are shown in table one.
Reprimo 824G>C P53R2 4696C>G
A CA TA GA A A GG T T TA T
GG GG
T TA G G G C G C AG AA C A C ATA G A A A G G  T T TA T
GCGC
T TAG G G C G C A G A A  C A CA TA GA A A G C T T T AT
CC
Table 1. Reprimo and p53R2 sequenee chromograms.
Tests for Hardy-Weinberg equilibrium (Table 2).
The Hardy-Weinberg equilibrium is the relationship between gene frequencies and 
genotype frequencies found within large, stable, randomly mating populations
9 9where p"+2pq+q“=l and p and q are the frequencies of the alleles occurring in that 
population. Deviation from Hardy-Weinberg equilibrium can indicate disease 
association.
STUDENT DIVERTICULAR COLORECTALCANCER
POPULATIONPOPULATION DISEASE POPULATION
Observed (expected) genotypes
GG=24(23) GG=10(14) GG=13(17)
GC=41(43) GC=34(25) GC=55(46)
Reprimo 824 G>C
CC=21(20) CC=7(H) CC=26(30
Allele frequencies
G=0.52 G=0.53 G=0.43
C=0.48 C=0.47 C=0.57
Exact test (1 degree of freedom)
P=0.67 P=0.03 P=0.09
Observed (expected) genotypes
GG=2(1) 
GC=11(14) 
CC=77(76)
GG=1(0)
GC=2(4)
CC=46(45)
GG=1(1)
GC=12(I3)
CC=82(82)
P53R2 4696C>G Allele frequencies
G=0.08 G=0.04
G=0.07
C=0.92 C=0.96 C=0.93
Exact test (1 degree of freedom)
P=0.10 P=0.06 P=0.40
Table 2. Tests for Hardy-Weinberg Equilibrium. Statistically significant results are 
shown in red.
All three populations were in Hardy-Weinberg equilibrium with respect to the 
p53R2 C>G 4696 SNP. The student and colorectal cancer populations were in 
Hardy-Weinberg equilibrium with respect to the Reprimo G>C 824 SNP but the 
diverticular disease population was in deviation from Hardy-Weinberg equilibrium 
(p=0.03) with an excess of heterozygotes and lack of both homozygotes.
Tests for disease association (Tables 3 and 4).
No associations between Reprimo 824 G>C or p53R2 C>G SNPs and CRC were 
demonstrated in this study.
TESTS FOR ASSOCIATION 
(95% CONFIDENCE INTERVALS)
SNP Populationstested
Allele 
frequency 
difference 
(1 df)
Heterozygous Homozygous Allelepositivity
Armitage’s 
trend test
C ALLELE
G v .C GGv. GC GG v. CC GG v. GC+CC
Common 
odds ratio
CRC v. DD 
(matched
O.R.=1.49 
C.I =0.92- 
2.41 
X2=2.58 
P=0.11
O.R.=1.24
C.I.=0.49-
3.15
X2=0.21
P=0.64
O.R.=2.86
C.I.=0.88-
9.23
X2=3.18
P=0.08
O.R.=1.52
C.I.=0.61-
3.76
X2=0.83
P=0.36
O.R.=1.70
X2=3.37
P=0.07
control) G ALLELE
C v.G CC v. GC CC v. GG
GG+GC 
v. CC
Common 
odds ratio
Reprimo
O.R.=0.67
C.I.=0.42-
1.09
X2=2.58
P=0.11
O.R.=0.44 
C.I.=0.17- 
1.11 
X2=3.11 
P=0.08
O.R.=0.35
C.I.=0.11-
1.13
X2=3.18
P=0.08
O.R.=0.42
C.I.=0.17-
1.10
X2=3.65
P=0.06
O.R.=0.59
X2=3.37
P=0.07
824
G>C
C ALLELE
G v .C GG v. GC GG v. CC GG v. GC+CC
Common 
odds ratio
CRC v. 
young 
healthy
O.R.=1.23
C.I.=0.81-
1.87
X2=0.97
P=0.33
O.R.=2.17
C.I.=0.97-
4.83
X2=3.65
P=0.06
O.R.=1.75
C.I.=0.72-
4.25
X2=1.54
P=0.21
O.R.=2.01
C.I.=0.94-
4.33
X2=3.29
P=0.07
O.R.=1.29
X2=1.05
P=0.31
(unmatched
control)
G ALLELE
C v. G CC v. GC CC v. GG GG+GC v. CC
Common 
odds ratio
O.R.=0.81
C.I.=0.54-
1.23
X2=0.97
P=0.33
O.R.=1.24
C.I.=0.62-
2.46
X2=0.37
P=0.54
O.R.=0.57
C.I.=0.24-
1.39
X2=1.54
P=0.21
O.R.=1.01
C.I.=0.53-
1.95
X2=0.00
P=0.97
O.R.=0.78
X2=1.05
P=0.31
Table 3. Tests for CRC association of Reprimo 824 G>C SNP.
TESTS FOR ASSOCIATION 
(95% CONFIDENCE INTERVALS
SNP Populatio ns tested
Allele 
frequency 
difference 
(1 df)
Hetero­
zygous
Homo­
zygous
Allele
positivity
Armitage’s 
trend test
C ALLELE
G v .C GG v. GC GG v. CC GG v. GC+CC
Common odds 
ratio
CRC v.
DD
(matched
control)
O.R. = 0.54 
C.I.=0.17- 
1.67 
x2= 1.19
p=0.27
O.R. = 6.00
C.I.=0.26 -  
140.05 
X2= 1-47 
P=0.23
O.R. = 1.78 
0 = 0 .1 1 -  
29.18 
X2=0.17
p=0.68
O.R. = 1.96 
0 = 0 .1 2 -  
32.00 
X^O.23 
p=0.63
O.R. = 0.75 
X2=1.02 
p=0.31
G ALLELE
C v. G CC V. GC CC V. GG GG+GC v. CC
Common odds 
ratio
p53R2
4696
O.R. = 1.87 
C.I.=0.60- 
5.84 
X2=1.19
p=0.28
O.R.=3.37 
0 = 0 .7 2 -  
15.70 
X2= 2.64
p=0.10
O.R.=0.56
0 = 0 .0 3 -
9.18
X-0.17
p=0.68
O.R. =2.43 
C.I.=0.66- 
8.98 
X2-l-87  
p=0.17
O.R.=1.43
x2'  1-02
p=0.31
C>G C ALLELE
G v .C GG v. GC GG v. CC GG v. GC+CC
Common odds 
ratio
CRC v. 
young 
healthy
O.R.=1.14
C.I.=0.54-
2.44
X2=0.12
p=0.73
O.R.=2.18 
0 = 0 .1 7 -  
27.56 
X2= 0.38 
p=0.54
O.R.=2.13 
0 = 0 .1 9 -  
23.97 
X2= 0.39 
p=0.53
O.R =2.14 
C.I.=0.19- 
23.98 
X2= 0.40 
p=0.53
O.R.=1.20
x2=o.io
p=0.75
(un­ G ALLELE
matched
control) C v .G CC v. GC CC v. GG
GG+GC v. 
CC
Common odds 
ratio
O.R.=0.88
C.I.=0.41-
1.87
X2=0.12
p=0.73
O.R.=1.02
0 = 0 .4 3 -
2.46
x2=o.oo
p=0.96
O.R.=0.47
0 = 0 .0 4 -
5.28
X2=0.39
p=0.53
O.R.=0.94
C.I.=0.41-
2.15
X-0.02
p=0.88
O.R.=0.86
X2=0.10
p=0.75
Table 4. Tests for CRC association with p53R2 4696 C>G.
Discussion
This study did not find any statistically significant association between the p53R2 
4696C>G or the Reprimo 824 G>C SNPs and CRC. The possibility that the SNPs 
may influence the age of onset of CRC should be considered, however this aspect 
was not examined in this study.
An unexpected finding, the Diverticular disease control population was shown to be 
in deviation from Hardy-Weinberg equilibrium with respect to the Reprimo 824 
G>C SNP, with an excess of heterozygotes and lack of both G and C homozygotes. 
The usual causes of deviation from Hardy-Weinberg equilibrium, inbreeding, 
genetic drift, small population size and selection pressure [24] cannot explain this 
finding in a large, randomly mating, static and late onset disease population. 
Deviation from Hardy-Weinberg may also be due to genotyping errors or 
population stratification [25], however genotyping was shown to be accurate by 
independent laboratory sequencing of DNA in all sample populations. If none of 
these factors are causing the deviation from Hardy-Weinberg equilibrium seen in 
the Diverticular disease population it may be due to genetic association [26]. The 
mechanism of this association is obscure, however. Heterozygotes have been shown 
to alter gene function [27] and survival advantage due to increased heterozygote 
fitness is termed heterosis, however diverticular disease does not affect biological 
fitness. However in this study it is the combination of the G and C alleles in the 
heterozygote that is associated with the diverticular disease phenotype.
Diverticular disease is not generally considered a “genetic disease”, however 
association between Far Eastern populations and right-sided diverticula [28] and 
diverticulosis in young adults with connective tissue disorders such as Marfan’s and 
Ehlers-Danlos syndromes suggest that molecular pathology may play a role [29,
30]. Similarly, extra cellular matrix alterations, colonic wall elastosis and altered 
collagen structure in the pathogenesis of diverticular disease [31] may be due to 
altered matrix metalloproteinases activity [32]. Genetic variants in the human 
metalloproteinases-2 gene have been discovered and SNPs located within the 
promoter region of the gene display functional variation [33]. A role for Reprimo in 
diverticular disease remains subject to further research. However it could be 
speculated that impaired DNA repair due to augmented Reprimo function could
alter the colonic extracellular matrix favouring diverticulosis formation. 
Alternatively Reprimo may have a role in symptom development in Diverticular 
disease via its effects on DNA repair and cellular proliferation.
Therefore it may be that diverticular disease has complex gene-environment 
aetiology and further studies are required to investigate its molecular pathology.
Conclusions
There are no associations between the p53R2 4649 C>G or Reprimo 824 G>C SNP 
SNPs and colorectal cancer demonstrated in this study.
There is an association between the Reprimo 824 G>C heterozygote and 
diverticular disease on the basis of deviation from Hardy-Weinberg equilibrium.
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